Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Neoplasms of the CNS

  Free Subscription


Articles published in Neuro Oncol

Retrieve available abstracts of 645 articles:
HTML format



Single Articles


    August 2022
  1. RUDA R, Capper D, Waldman AD, Pallud J, et al
    Eano-Euracan-Sno Guidelines on Circumscribed Astrocytic GLIOMAS, Glioneuronal and Neuronaltumors.
    Neuro Oncol. 2022 Aug 1. pii: 6652587. doi: 10.1093.
    PubMed     Abstract available


  2. BOELE FW, den Otter PWM, Reijneveld JC, de Witt Hamer PC, et al
    Long-term wellbeing and neurocognitive functioning of diffuse low-grade glioma patients and their caregivers: a longitudinal study spanning two decades.
    Neuro Oncol. 2022 Aug 1. pii: 6652588. doi: 10.1093.
    PubMed     Abstract available


  3. VARADHARAJAN S, Mack SC
    Leveraging epigenomic patterns to resolve the heterogeneity and origins of CNS germ cell tumors.
    Neuro Oncol. 2022;24:1259-1260.
    PubMed    


  4. DESJARDINS A
    Improving survival in neuro-oncology is a struggle; we cannot allow ourselves to also struggle with issues of diversity.
    Neuro Oncol. 2022;24:1350-1351.
    PubMed    


  5. YAO H, Xie W, Dai Y, Liu Y, et al
    TRIM65 determines the fate of a novel subtype of pituitary neuroendocrine tumors via ubiquitination and degradation of TPIT.
    Neuro Oncol. 2022;24:1286-1297.
    PubMed     Abstract available


  6. TAKAMI H, Elzawahry A, Mamatjan Y, Fukushima S, et al
    Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterparts.
    Neuro Oncol. 2022;24:1246-1258.
    PubMed     Abstract available


  7. KOH KN, Wong RX, Lee DE, Han JW, et al
    Outcomes of intracranial germinoma-A retrospective multinational Asian study on effect of clinical presentation and differential treatment strategies.
    Neuro Oncol. 2022;24:1389-1399.
    PubMed     Abstract available


    July 2022
  8. HERTLER C, Seystahl K, Le Rhun E, Wirsching HG, et al
    Improved seizure control in patients with recurrent glioblastoma treated with bevacizumab.
    Neuro Oncol. 2022 Jul 30. pii: 6652283. doi: 10.1093.
    PubMed    



  9. Erratum to: Environmental and sex-specific molecular signatures of glioma causation.
    Neuro Oncol. 2022 Jul 29. pii: 6651886. doi: 10.1093.
    PubMed    


  10. CHEN AT, Xiao Y, Tang X, Baqri M, et al
    Cross-platform analysis reveals cellular and molecular landscape of glioblastoma invasion.
    Neuro Oncol. 2022 Jul 28. pii: 6651351. doi: 10.1093.
    PubMed     Abstract available


  11. SIGAUD R, Rosch L, Gatzweiler C, Benzel J, et al
    The first-in-class ERK inhibitor ulixertinib shows promising activity in MAPK-driven pediatric low-grade glioma models.
    Neuro Oncol. 2022 Jul 27. pii: 6650335. doi: 10.1093.
    PubMed     Abstract available


  12. DREXLER R, Schuller U, Eckhardt A, Filipski K, et al
    DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients.
    Neuro Oncol. 2022 Jul 22. pii: 6648783. doi: 10.1093.
    PubMed     Abstract available


  13. WALSH KM, Neff C, Bondy ML, Kruchko C, et al
    Influence of county-level geographic/ancestral origin on glioma incidence and outcomes in US Hispanics.
    Neuro Oncol. 2022 Jul 22. pii: 6648782. doi: 10.1093.
    PubMed     Abstract available


  14. KOSTI A, Chiou J, Guardia GDA, Lei X, et al
    ELF4 is a critical component of a miRNA-transcription factor network and is a bridge regulator of glioblastoma receptor signaling and lipid dynamics.
    Neuro Oncol. 2022 Jul 21. pii: 6648020. doi: 10.1093.
    PubMed     Abstract available


  15. LASSMAN AB, Pugh SL, Wang TJC, Aldape K, et al
    Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial.
    Neuro Oncol. 2022 Jul 15. pii: 6645128. doi: 10.1093.
    PubMed     Abstract available


  16. BUEHLER M, Yi X, Ge W, Blattmann P, et al
    Quantitative proteomic landscapes of primary and recurrent glioblastoma reveal a protumorigeneic role for FBXO2-dependent glioma-microenvironment interactions.
    Neuro Oncol. 2022 Jul 8. pii: 6634186. doi: 10.1093.
    PubMed     Abstract available


  17. REYES-GONZALEZ J, Barajas-Olmos F, Garcia-Ortiz H, Magraner-Pardo L, et al
    Brain Radiotoxicity-Related 15CAcBRT Gene Expression Signature Predicts Survival Prognosis of Glioblastoma Patients.
    Neuro Oncol. 2022 Jul 8. pii: 6634161. doi: 10.1093.
    PubMed     Abstract available


  18. VAN DER VOORT SR, Incekara F, Wijnenga MMJ, Kapsas G, et al
    Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning.
    Neuro Oncol. 2022 Jul 5. pii: 6631283. doi: 10.1093.
    PubMed     Abstract available


  19. HUSE JT
    A Promising Preclinical Model For Tert Promoter Mutation In Glioblastoma.
    Neuro Oncol. 2022 Jul 3. pii: 6628220. doi: 10.1093.
    PubMed    


  20. DONAHUE BR, MacDonald S
    Protons for pediatric ependymoma: Where are we now?
    Neuro Oncol. 2022;24:1203-1204.
    PubMed    


  21. MILLWARD CP, Armstrong TS, Barrington H, Brodbelt AR, et al
    Opportunities and challenges for the development of "core outcome sets" in neuro-oncology.
    Neuro Oncol. 2022;24:1048-1055.
    PubMed     Abstract available


  22. HERRGOTT GA, Asmaro KP, Wells M, Sabedot TS, et al
    Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.
    Neuro Oncol. 2022;24:1126-1139.
    PubMed     Abstract available


  23. PETERS S, Merta J, Schmidt L, Jazmati D, et al
    Evaluation of dose, volume, and outcome in children with localized, intracranial ependymoma treated with proton therapy within the prospective KiProReg Study.
    Neuro Oncol. 2022;24:1193-1202.
    PubMed     Abstract available


    June 2022
  24. PALMER JD, Prasad RN, Cioffi G, Kruchtko C, et al
    Exposure to Radon and Heavy Particulate Pollution and Incidence of Brain Tumors.
    Neuro Oncol. 2022 Jun 28. pii: 6618967. doi: 10.1093.
    PubMed     Abstract available


  25. AIZER AA, Lamba N, Ahluwalia MS, Aldape K, et al
    Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.
    Neuro Oncol. 2022 Jun 28. pii: 6618874. doi: 10.1093.
    PubMed     Abstract available


  26. NOBRE L, Bouffet E
    BRAF inhibitors in BRAFV600E mutated pediatric high-grade gliomas: upfront or at recurrence?
    Neuro Oncol. 2022 Jun 24. pii: 6617660. doi: 10.1093.
    PubMed    


  27. WEISHAUPT H, Cancer M, Rosen G, Holmberg KO, et al
    Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas.
    Neuro Oncol. 2022 Jun 23. pii: 6615415. doi: 10.1093.
    PubMed     Abstract available


  28. CHEN X, Niu W, Fan X, Yang H, et al
    Oct4A palmitoylation modulates tumorigenicity and stemness in human glioblastoma cells.
    Neuro Oncol. 2022 Jun 21. pii: 6612239. doi: 10.1093.
    PubMed     Abstract available


  29. WANG Y, Wang K, Fu J, Zhang Y, et al
    FRK inhibits glioblastoma progression via phosphorylating YAP and inducing its ubiquitylation and degradation by Siah1.
    Neuro Oncol. 2022 Jun 20. pii: 6611687. doi: 10.1093.
    PubMed     Abstract available


  30. NATSUME A, Arakawa Y, Narita Y, Sugiyama K, et al
    The first-in-human phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.
    Neuro Oncol. 2022 Jun 20. pii: 6611503. doi: 10.1093.
    PubMed     Abstract available


  31. LIU XP, Jin X, Ahmadian SS, Yang X, et al
    Clinical Significance and Molecular Annotation of Cellular Morphometric Subtypes in Lower Grade Gliomas discovered by Machine Learning.
    Neuro Oncol. 2022 Jun 18. pii: 6611075. doi: 10.1093.
    PubMed     Abstract available


  32. OSTROM QT, Lu D, Lu R, Baker MC, et al
    Prevalence of autoimmunity and atopy in US adults with glioblastoma and meningioma.
    Neuro Oncol. 2022 Jun 17. pii: 6609733. doi: 10.1093.
    PubMed    


  33. SARAF A, Yock TI, Niemierko A, Oh KS, et al
    Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: a contemporary single-institution experience.
    Neuro Oncol. 2022 Jun 7. pii: 6603917. doi: 10.1093.
    PubMed     Abstract available


  34. LEE-CHANG C
    Understanding the relationship between gliomas and T cells: Paving the way for effective immunotherapy.
    Neuro Oncol. 2022 Jun 6. pii: 6602133. doi: 10.1093.
    PubMed    


  35. ROGERS CL, Pugh SL, Vogelbaum MA, Perry A, et al
    Low-Risk Meningioma: Initial Outcomes from NRG Oncology/RTOG 0539.
    Neuro Oncol. 2022 Jun 3. pii: 6601387. doi: 10.1093.
    PubMed     Abstract available


  36. POON MTC, Brennan PM, Jin K, Sudlow CLM, et al
    Standardizing reporting of brain and central nervous system tumors in the United Kingdom.
    Neuro Oncol. 2022;24:1032-1033.
    PubMed    


  37. MANGUM R, Parsons DW
    TRK inhibition for pediatric and adult central nervous system tumors: Early promise and future questions.
    Neuro Oncol. 2022;24:1008-1009.
    PubMed    


  38. FAROUK SAIT S, Karajannis MA
    Chemotherapy plus focal radiation therapy for localized intracranial germinoma: How little is enough?
    Neuro Oncol. 2022;24:984-985.
    PubMed    


  39. CAI F, Chen S, Yu X, Zhang J, et al
    Transcription factor GTF2B regulates AIP protein expression in growth hormone-secreting pituitary adenomas and influences tumor phenotypes.
    Neuro Oncol. 2022;24:925-935.
    PubMed     Abstract available


  40. BARTELS U, Onar-Thomas A, Patel SK, Shaw D, et al
    Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study.
    Neuro Oncol. 2022;24:974-983.
    PubMed     Abstract available


  41. PARK AK, Waheed A, Forst DA, Al-Samkari H, et al
    Characterization and prognosis of temozolomide-induced aplastic anemia in patients with central nervous system malignancies.
    Neuro Oncol. 2022;24:964-973.
    PubMed     Abstract available


    May 2022

  42. Erratum to: Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma.
    Neuro Oncol. 2022 May 27. pii: 6594729. doi: 10.1093.
    PubMed    


  43. NOBRE L, Hawkins C
    Liquid biopsy for pediatric brain tumor patients: is it prime time yet?
    Neuro Oncol. 2022 May 27. pii: 6593987. doi: 10.1093.
    PubMed    


  44. VERPLOEGH ISC, Conidi A, Brouwer RWW, Balcioglu HE, et al
    Comparative single-cell RNA-sequencing profiling of BMP4-treated primary glioma cultures reveals therapeutic markers.
    Neuro Oncol. 2022 May 26. pii: 6593858. doi: 10.1093.
    PubMed     Abstract available


  45. DE LA FUENTE MI, Colman H, Rosenthal M, Van Tine BA, et al
    Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: a multicenter, open-label, phase 1b/2 trial.
    Neuro Oncol. 2022 May 25. pii: 6593129. doi: 10.1093.
    PubMed     Abstract available


  46. FRIEDRICH M, Hahn M, Michel J, Sankowski R, et al
    Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
    Neuro Oncol. 2022 May 24. pii: 6591514. doi: 10.1093.
    PubMed     Abstract available


  47. GRIGUOLO G, Tosi A, Dieci MV, Fineberg S, et al
    A comprehensive profiling of the immune microenvironment of breast cancer brain metastases.
    Neuro Oncol. 2022 May 24. pii: 6591493. doi: 10.1093.
    PubMed     Abstract available


  48. MESSINGER D, Harris MK, Cummings JR, Thomas C, et al
    Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma.
    Neuro Oncol. 2022 May 23. pii: 6590903. doi: 10.1093.
    PubMed     Abstract available


  49. YEO KK, Alexandrescu S, Cotter JA, Vogelzang J, et al
    Multi-institutional study of the frequency, genomic landscape and outcome of IDH-mutant glioma in paediatrics.
    Neuro Oncol. 2022 May 23. pii: 6590765. doi: 10.1093.
    PubMed     Abstract available


  50. GIRARDI F, Coleman MP, Allemani C
    Reply to "Reporting pediatric brain tumors according to their behavior code can result in biased survival estimates-A European perspective to Girardi et al".
    Neuro Oncol. 2022 May 21. pii: 6590321. doi: 10.1093.
    PubMed    


  51. HOOGENDIJK R, van der Lugt J, van Vuurden DG, Visser O, et al
    Reporting pediatric brain tumors according to their behavior code can result in biased survival estimates-A European perspective to Girardi et al.
    Neuro Oncol. 2022 May 21. pii: 6590318. doi: 10.1093.
    PubMed    


  52. EDMONSTON DY, Wu S, Li Y, Khan RB, et al
    Limited Surgery and Conformal Photon Radiation Therapy for Pediatric Craniopharyngioma: Long-term Results from the RT1 Protocol.
    Neuro Oncol. 2022 May 12. pii: 6585053. doi: 10.1093.
    PubMed     Abstract available


  53. SAMPETREAN O, Saya H
    What can metabolites tell us about gliomas?
    Neuro Oncol. 2022 May 12. pii: 6584800. doi: 10.1093.
    PubMed    


  54. BARTLETT A, Lane A, Chaney B, Escorza NY, et al
    Characteristics of Children
    Neuro Oncol. 2022 May 12. pii: 6585024. doi: 10.1093.
    PubMed     Abstract available


  55. RICKLEFS FL, Maire CL, Wollmann K, Duhrsen L, et al
    Diagnostic potential of extracellular vesicles in meningioma patients.
    Neuro Oncol. 2022 May 12. pii: 6585054. doi: 10.1093.
    PubMed     Abstract available


  56. REED-GUY L, Desai AS, Phillips RE, Croteau D, et al
    Risk of intracranial hemorrhage with direct oral anticoagulants versus low molecular weight heparin in glioblastoma: A retrospective cohort study.
    Neuro Oncol. 2022 May 12. pii: 6585055. doi: 10.1093.
    PubMed     Abstract available


  57. ROESLER R, de Farias CB, Brunetto AT, Gregianin L, et al
    Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastoma.
    Neuro Oncol. 2022 May 11. pii: 6584501. doi: 10.1093.
    PubMed    



  58. Erratum to: path-03. Ferroptosis-related long non-coding rna signatures predict prognosis in patients with glioma.
    Neuro Oncol. 2022 May 9. pii: 6583332. doi: 10.1093.
    PubMed    


  59. WINKLER F
    Understanding epilepsy in IDH-mutated gliomas: towards a targeted therapy.
    Neuro Oncol. 2022 May 9. pii: 6582767. doi: 10.1093.
    PubMed    


  60. GALLDIKS N, Lohmann P, Langen KJ
    The role of 11C-methionine PET in patients with newly diagnosed WHO grade 2 or 3 gliomas.
    Neuro Oncol. 2022 May 5. pii: 6581471. doi: 10.1093.
    PubMed    


  61. CASES-CUNILLERA S, van Loo KMJ, Pitsch J, Quatraccioni A, et al
    Heterogeneity and excitability of BRAFV600E-induced tumors is determined by Akt/mTOR-signaling state and Trp53-loss.
    Neuro Oncol. 2022;24:741-754.
    PubMed     Abstract available


  62. SATOMI K, Takami H, Fukushima S, Yamashita S, et al
    12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors.
    Neuro Oncol. 2022;24:834-846.
    PubMed     Abstract available


  63. LAZOW MA, Fuller C, DeWire M, Lane A, et al
    Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry.
    Neuro Oncol. 2022;24:821-833.
    PubMed     Abstract available


  64. RUDA R, Bruno F, Ius T, Silvani A, et al
    IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups.
    Neuro Oncol. 2022;24:809-820.
    PubMed     Abstract available


  65. FELIX M, Friedel D, Jayavelu AK, Filipski K, et al
    HIP1R and Vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
    Neuro Oncol. 2022 May 3. pii: 6578556. doi: 10.1093.
    PubMed     Abstract available


  66. RICKLEFS FL, Drexler R, Wollmann K, Eckhardt A, et al
    DNA Methylation subclass Receptor Tyrosine Kinase II (RTK II) is predictive for seizure development in glioblastoma patients.
    Neuro Oncol. 2022 May 2. pii: 6577052. doi: 10.1093.
    PubMed     Abstract available


  67. LIM M, Weller M, Idbaih A, Steinbach J, et al
    Phase 3 Trial of Chemoradiotherapy With Temozolomide Plus Nivolumab or Placebo for Newly Diagnosed Glioblastoma With Methylated MGMT Promoter.
    Neuro Oncol. 2022 May 2. pii: 6577049. doi: 10.1093.
    PubMed     Abstract available


    April 2022
  68. PERSSON ML, Douglas AM, Alvaro F, Faridi P, et al
    The intrinsic and microenvironmental features of diffuse midline glioma; implications for the development of effective immunotherapeutic treatment strategies.
    Neuro Oncol. 2022 Apr 27. pii: 6575144. doi: 10.1093.
    PubMed     Abstract available


  69. MERCHANT TE, Edmonston DY, Wu S, Li Y, et al
    Endocrine Outcomes after Limited Surgery and Conformal Photon Radiation Therapy for Pediatric Craniopharyngioma: Long-term Results from the RT1 Protocol.
    Neuro Oncol. 2022 Apr 27. pii: 6575137. doi: 10.1093.
    PubMed     Abstract available


  70. DING J, Li X, Khan S, Zhang C, et al
    EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a non-canonical regulatory axis between EGFR and wild-type p53 in glioblastoma.
    Neuro Oncol. 2022 Apr 26. pii: 6574563. doi: 10.1093.
    PubMed     Abstract available


  71. GUTIERREZ-VALENCIA E, Kalyvas A, Villafuerte CJ, Millar BA, et al
    Factors Correlating with Survival Following Adjuvant or Definitive Radiosurgery for Large Brain Metastases.
    Neuro Oncol. 2022 Apr 26. pii: 6574580. doi: 10.1093.
    PubMed     Abstract available


  72. JAIN B, Dee EC, Jain U, Aizer AA, et al
    Trends in location of death for individuals with primary brain tumors in the United States.
    Neuro Oncol. 2022 Apr 26. pii: 6574444. doi: 10.1093.
    PubMed    


  73. SCHONROCK A, Heinzelmann E, Steffl B, Demirdizen E, et al
    MEOX2 homeobox gene promotes growth of malignant gliomas.
    Neuro Oncol. 2022 Apr 25. pii: 6573906. doi: 10.1093.
    PubMed     Abstract available


  74. MA R, Rei M, Woodhouse I, Ferris K, et al
    Decitabine increases neoantigen and cancer testis antigen expression to enhance T cell-mediated toxicity against glioblastoma.
    Neuro Oncol. 2022 Apr 25. pii: 6573935. doi: 10.1093.
    PubMed     Abstract available


  75. MINAMI N, Hong D, Stevers N, Barger CJ, et al
    Imaging biomarkers of TERT or GABPB1 silencing in TERT-positive glioblastoma.
    Neuro Oncol. 2022 Apr 23. pii: 6573305. doi: 10.1093.
    PubMed     Abstract available


  76. IORGULESCU JB, Sun C, Neff C, Cioffi G, et al
    Molecular Biomarker-Defined Brain Tumors: Epidemiology, Validity, and Completeness in the United States.
    Neuro Oncol. 2022 Apr 23. pii: 6573306. doi: 10.1093.
    PubMed     Abstract available


  77. CHUNG C, Brown PD, Wefel JS
    Lessons learned from proton vs photon radiation therapy for glioblastoma signal-finding trial.
    Neuro Oncol. 2022 Apr 23. pii: 6573235. doi: 10.1093.
    PubMed    


  78. PUROW B
    ONC201 and ONC206: metabolically ClipPing the wings of diffuse midline glioma.
    Neuro Oncol. 2022 Apr 23. pii: 6573255. doi: 10.1093.
    PubMed    


  79. OMURO A, Brandes AA, Carpentier AF, Idbaih A, et al
    Radiotherapy Combined With Nivolumab or Temozolomide for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter: An International Randomized Phase 3 Trial.
    Neuro Oncol. 2022 Apr 14. pii: 6568419. doi: 10.1093.
    PubMed     Abstract available


  80. COUTURIER CP, Nadaf J, Li Z, Baig S, et al
    Glioblastoma scRNAseq Shows Treatment-induced, Immune-dependent Rise In Mesenchymal Cancer Cells, and Structural Variants in Distal Neural Stem Cells.
    Neuro Oncol. 2022 Apr 13. pii: 6567757. doi: 10.1093.
    PubMed     Abstract available


  81. COOMANS M, Dirven L, Aaronson N, Baumert BG, et al
    Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period.
    Neuro Oncol. 2022 Apr 11. pii: 6566436. doi: 10.1093.
    PubMed     Abstract available


  82. GHOSH S
    Breaking the DLG shackles in glioblastoma.
    Neuro Oncol. 2022 Apr 11. pii: 6566243. doi: 10.1093.
    PubMed    


  83. ROSENBERG T, Yeo KK, Mauguen A, Alexandrescu S, et al
    Upfront Molecular Targeted Therapy for the Treatment of BRAF-Mutant Pediatric High-Grade Glioma.
    Neuro Oncol. 2022 Apr 9. pii: 6566011. doi: 10.1093.
    PubMed     Abstract available


  84. ZHANG L, Nesvick CL, Day CA, Choi J, et al
    STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma.
    Neuro Oncol. 2022 Apr 9. pii: 6566009. doi: 10.1093.
    PubMed     Abstract available


  85. KANMOUNYE US, Karekezi C, Nyalundja AD, Awad AK, et al
    Adult brain tumors in Sub-Saharan Africa: A scoping review.
    Neuro Oncol. 2022 Apr 9. pii: 6566010. doi: 10.1093.
    PubMed     Abstract available


  86. ZHANG Y, Lucas CG, Young JS, Morshed RA, et al
    Prospective genomically-guided identification of 'early/evolving' and 'undersampled' IDH-wildtype glioblastoma leads to improved clinical outcomes.
    Neuro Oncol. 2022 Apr 8. pii: 6565639. doi: 10.1093.
    PubMed     Abstract available


  87. BIEGEL JA
    Meeting the high expectations for liquid biopsy assays for pediatric brain tumors: progress and challenges.
    Neuro Oncol. 2022 Apr 5. pii: 6563880. doi: 10.1093.
    PubMed    


  88. ELLINGSON BM, Gerstner ER, Lassman AB, Chung C, et al
    Hypothetical Generalized Framework for a New Imaging Endpoint of Therapeutic Activity in Early Phase Clinical Trials in Brain Tumors.
    Neuro Oncol. 2022 Apr 5. pii: 6563738. doi: 10.1093.
    PubMed     Abstract available


  89. TESILEANU CMS, Gorlia T, Golfinopoulos V, French PJ, et al
    MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas.
    Neuro Oncol. 2022;24:665-667.
    PubMed    


  90. FRAPPAZ D, Dhall G, Murray MJ, Goldman S, et al
    EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults.
    Neuro Oncol. 2022;24:516-527.
    PubMed     Abstract available


  91. NAKAMURA H, Takami H, Yanagisawa T, Kumabe T, et al
    The Japan Society for Neuro-Oncology guideline on the diagnosis and treatment of central nervous system germ cell tumors.
    Neuro Oncol. 2022;24:503-515.
    PubMed     Abstract available


  92. WU Z, Abdullaev Z, Pratt D, Chung HJ, et al
    Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics.
    Neuro Oncol. 2022;24:571-581.
    PubMed     Abstract available


    March 2022
  93. SARAN F, Eisenstat DD
    The relapse doesn't fall far from the radiotherapy field: Lessons to be learned for the future of radiotherapy in medulloblastoma from the relapse patterns of SJMB03.
    Neuro Oncol. 2022 Mar 24. pii: 6553345. doi: 10.1093.
    PubMed    


  94. PIOTROWSKI AF, Jackson S
    Identifying risk factors for recurrence/relapse in NF1 optic pathway gliomas: Moving forward by looking back.
    Neuro Oncol. 2022 Mar 23. pii: 6553267. doi: 10.1093.
    PubMed    


  95. CORDELL EC, Alghamri MS, Castro MG, Gutmann DH, et al
    T lymphocytes as dynamic regulators of glioma pathobiology.
    Neuro Oncol. 2022 Mar 23. pii: 6553145. doi: 10.1093.
    PubMed     Abstract available


  96. OSUKA S
    Targeting adaptive radioresistance in Glioblastoma.
    Neuro Oncol. 2022 Mar 22. pii: 6552309. doi: 10.1093.
    PubMed    


  97. BLOBNER J, Tonn JC
    Resection of glioma - Feeding the beast?
    Neuro Oncol. 2022 Mar 22. pii: 6552311. doi: 10.1093.
    PubMed    


  98. AZAD TD, Bettegowda C
    Longitudinal monitoring of diffuse midline glioma using liquid biopsy.
    Neuro Oncol. 2022 Mar 22. pii: 6552310. doi: 10.1093.
    PubMed    


  99. LE RHUN E, Oppong FB, Vanlancker M, Stupp R, et al
    Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.
    Neuro Oncol. 2022 Mar 21. pii: 6551573. doi: 10.1093.
    PubMed     Abstract available


  100. ZHAN Q, Yi K, Cui X, Li X, et al
    Blood exosomes-based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy.
    Neuro Oncol. 2022 Mar 21. pii: 6551550. doi: 10.1093.
    PubMed     Abstract available


  101. QIN N, Paisana E, Langini M, Picard D, et al
    Intratumoral heterogeneity of MYC drives medulloblastoma metastasis and angiogenesis.
    Neuro Oncol. 2022 Mar 21. pii: 6551011. doi: 10.1093.
    PubMed     Abstract available


  102. FANGUSARO JR, Onar-Thomas A, Poussaint TY, Wu S, et al
    Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.
    Neuro Oncol. 2022 Mar 21. pii: 6551018. doi: 10.1093.
    PubMed    


  103. FERDOSI SR, Taylor B, Lee M, Tang N, et al
    PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitors.
    Neuro Oncol. 2022 Mar 19. pii: 6550856. doi: 10.1093.
    PubMed     Abstract available


  104. BOUFFET E, Lafay-Cousin L
    Infant brain tumor trials: Beyond feasibility.
    Neuro Oncol. 2022 Mar 14. pii: 6548388. doi: 10.1093.
    PubMed    


  105. ZHOU Y, Meng X, He W, Li XY, et al
    USF1/CD90 signaling in maintaining glioblastoma stem cells and tumor-associated macrophages adhesion.
    Neuro Oncol. 2022 Mar 14. pii: 6548387. doi: 10.1093.
    PubMed     Abstract available


  106. MOHAMED E, Kumar A, Zhang Y, Wang AS, et al
    PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.
    Neuro Oncol. 2022 Mar 14. pii: 6548389. doi: 10.1093.
    PubMed     Abstract available


  107. FOREMAN NK
    Outcomes after first relapse of children with intracranial ependymoma treated on the second l'Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP) protocol.
    Neuro Oncol. 2022;24:480-481.
    PubMed    


  108. MILLER JJ, Wang N
    Body imaging for newly diagnosed CNS lymphoma: Evaluating the utility of the evaluation.
    Neuro Oncol. 2022;24:492-493.
    PubMed    


  109. MASSIMINO M, Barretta F, Modena P, Johann P, et al
    Treatment and outcome of intracranial ependymoma after first relapse in the 2nd AIEOP protocol.
    Neuro Oncol. 2022;24:467-479.
    PubMed     Abstract available


  110. BURGENSKE DM, Talele S, Pokorny JL, Mladek AC, et al
    Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
    Neuro Oncol. 2022;24:384-395.
    PubMed     Abstract available


  111. MILLER JJ, Cahill DP, Arrillaga-Romany I
    Enhancing demethylation-induced differentiation in IDH-mutant glioma.
    Neuro Oncol. 2022 Mar 3. pii: 6542042. doi: 10.1093.
    PubMed    


  112. MLADEK AC, Yan H, Tian S, Decker PA, et al
    RBBP4-p300 Axis Modulates Expression of Genes Essential for Cell Survival and is a Potential Target for Therapy in Glioblastoma.
    Neuro Oncol. 2022 Mar 1. pii: 6540482. doi: 10.1093.
    PubMed     Abstract available


    February 2022
  113. BADODI S, Pomella N, Lim YM, Brandner S, et al
    Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma.
    Neuro Oncol. 2022 Feb 25. pii: 6537125. doi: 10.1093.
    PubMed     Abstract available


  114. PAPUSHA L, Zaytseva M, Panferova A, Druy A, et al
    Two clinically distinct cases of infant hemispheric glioma carrying ZCCHC8:ROS1 fusion and responding to entrectinib.
    Neuro Oncol. 2022 Feb 23. pii: 6535118. doi: 10.1093.
    PubMed    


  115. FERRARESE R, Carro MS
    Neural networks help zebrafish to step up as a model for efficient drug screening in glioblastoma.
    Neuro Oncol. 2022 Feb 19. pii: 6532496. doi: 10.1093.
    PubMed    


  116. NINATTI G, Sollini M, Bono B, Gozzi N, et al
    Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas.
    Neuro Oncol. 2022 Feb 16. pii: 6529477. doi: 10.1093.
    PubMed     Abstract available


  117. UPADHYAY R, Liao K, Grosshans DR, McGovern SL, et al
    Quantifying the risk and dosimetric variables of symptomatic brainstem injury after proton beam radiation in pediatric brain tumors.
    Neuro Oncol. 2022 Feb 14. pii: 6528473. doi: 10.1093.
    PubMed     Abstract available


  118. PRZYSTAL JM, Cosentino CC, Yadavilli S, Zhang J, et al
    Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.
    Neuro Oncol. 2022 Feb 14. pii: 6528446. doi: 10.1093.
    PubMed     Abstract available


  119. BJORKBLOM B, Wibom C, Eriksson M, Bergenheim AT, et al
    Distinct metabolic hallmarks of WHO classified adult glioma subtypes.
    Neuro Oncol. 2022 Feb 14. pii: 6528465. doi: 10.1093.
    PubMed     Abstract available


  120. LIU T, Zhu C, Chen X, Guan G, et al
    Ferroptosis, as the most enriched programmed cell death process in glioma, induces immunosuppression and immunotherapy resistance.
    Neuro Oncol. 2022 Feb 11. pii: 6527229. doi: 10.1093.
    PubMed     Abstract available


  121. MILLER AM, Szalontay L, Bouvier N, Hill K, et al
    Next-generation Sequencing of Cerebrospinal Fluid for Clinical Molecular Diagnostics in Pediatric, Adolescent and Young Adult (AYA) Brain Tumor Patients.
    Neuro Oncol. 2022 Feb 11. pii: 6527231. doi: 10.1093.
    PubMed     Abstract available


  122. VAN KESSEL E, Berendsen S, Baumfalk AE, Venugopal H, et al
    Tumor-related molecular determinants of neurocognitive deficits in patients with diffuse glioma.
    Neuro Oncol. 2022 Feb 11. pii: 6527233. doi: 10.1093.
    PubMed     Abstract available


  123. LAZOW MA, Nievelstein MT, Lane A, Bandopadhayhay P, et al
    Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry.
    Neuro Oncol. 2022 Feb 11. pii: 6527234. doi: 10.1093.
    PubMed     Abstract available


  124. REBCHUK AD, Chaharyn BM, Alam A, Hounjet CD, et al
    The Impact of Brain Invasion Criteria on the Incidence and Distribution of WHO Grade 1, 2 and 3 Meningiomas.
    Neuro Oncol. 2022 Feb 9. pii: 6525422. doi: 10.1093.
    PubMed     Abstract available


  125. JO J, van den Bent MJ, Nabors B, Wen PY, et al
    Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas.
    Neuro Oncol. 2022 Feb 8. pii: 6524653. doi: 10.1093.
    PubMed     Abstract available


  126. CANTOR E, Wierzbicki K, Tarapore RS, Ravi K, et al
    Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.
    Neuro Oncol. 2022 Feb 6. pii: 6523277. doi: 10.1093.
    PubMed     Abstract available


    January 2022
  127. YIN S, Luo X, Yang Y, Shao Y, et al
    Development and validation of a deep-learning model for detecting brain metastases on 3D post-contrast MRI: a multi-center multi-reader evaluation study.
    Neuro Oncol. 2022 Jan 31. pii: 6518101. doi: 10.1093.
    PubMed     Abstract available


  128. ALVAREZ-BRECKENRIDGE CA, Cahill DP, Brastianos PK
    Trabectedin for recurrent WHO grade 2 or 3 meningiomas-paving the road for new opportunities.
    Neuro Oncol. 2022 Jan 31. pii: 6518099. doi: 10.1093.
    PubMed    


  129. READ RD
    Repurposing the drug verteporfin as anti-neoplastic therapy for glioblastoma.
    Neuro Oncol. 2022 Jan 31. pii: 6518098. doi: 10.1093.
    PubMed    


  130. BROWN CE, Rodriguez A, Palmer J, Ostberg JR, et al
    Off-the-shelf, Steroid Resistant, IL13Ralpha2-Specific CAR T Cells for Treatment of Glioblastoma.
    Neuro Oncol. 2022 Jan 31. pii: 6518100. doi: 10.1093.
    PubMed     Abstract available


  131. LOWE SR, Wang CP, Brisco A, Whiting J, et al
    Surgical and Anatomic Factors Predict Development of Leptomeningeal Disease in Patients with Melanoma Brain Metastases.
    Neuro Oncol. 2022 Jan 29. pii: 6517353. doi: 10.1093.
    PubMed     Abstract available


  132. TAGLANG C, Batsios G, Mukherjee J, Tran M, et al
    Deuterium magnetic resonance spectroscopy enables non-invasive metabolic imaging of tumor burden and response to therapy in low-grade gliomas.
    Neuro Oncol. 2022 Jan 29. pii: 6517050. doi: 10.1093.
    PubMed     Abstract available


  133. GERSTNER ER
    Volumetric Measurements in Low Grade Glioma: Are we there yet?
    Neuro Oncol. 2022 Jan 28. pii: 6516793. doi: 10.1093.
    PubMed    


  134. KOEKKOEK JAF, van der Meer PB, Taphoorn MJB, Dirven L, et al
    Letter regarding "SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors".
    Neuro Oncol. 2022 Jan 25. pii: 6515357. doi: 10.1093.
    PubMed    


  135. PICCA A, Desjardins C, Bihan K, Weiss N, et al
    Progressive multifocal leukoencephalopathy after first-line radiotherapy and temozolomide for glioblastoma.
    Neuro Oncol. 2022 Jan 17. pii: 6509380. doi: 10.1093.
    PubMed    


  136. RAHMAN R, Huang RY
    Deep learning approaches to non-invasively assess molecular features of gliomas.
    Neuro Oncol. 2022 Jan 13. pii: 6507359. doi: 10.1093.
    PubMed    


  137. VOGELIUS IR, Bentzen SM
    Proton vs photon radiation therapy for glioblastoma: Maximizing information from trial.
    Neuro Oncol. 2022 Jan 13. pii: 6506534. doi: 10.1093.
    PubMed    


  138. BECKER KN, Eisenmann KM
    New Targets in the Glioblastoma Tumor Microtube Multiverse: Emerging Roles for the TGF-beta/TSP1 Signaling Axis.
    Neuro Oncol. 2022 Jan 10. pii: 6502470. doi: 10.1093.
    PubMed    


  139. TRAN AN
    Targeting glutamine addiction in meningioma.
    Neuro Oncol. 2022 Jan 10. pii: 6502476. doi: 10.1093.
    PubMed    


  140. ESPINOZA FI, Walker PR
    Untangling macrophage/microglia complexity in glioblastoma subtypes to elucidate the impact of CSF1R inhibition.
    Neuro Oncol. 2022 Jan 10. pii: 6502489. doi: 10.1093.
    PubMed    


  141. VOGELBAUM MA
    Balancing Maximal Resection and Functional Preservation in Surgery for Low Grade Glioma.
    Neuro Oncol. 2022 Jan 10. pii: 6502479. doi: 10.1093.
    PubMed    


  142. KOTCH C, Avery R, Getz KD, Bouffet E, et al
    Risk Factors for Treatment Refractory and Relapsed Optic Pathway Glioma in Children with Neurofibromatosis Type 1.
    Neuro Oncol. 2022 Jan 9. pii: 6501465. doi: 10.1093.
    PubMed     Abstract available


  143. MAEGAWA S, Gopalakrishnan V
    PLK inhibitors come of age in pediatric brain tumors.
    Neuro Oncol. 2022 Jan 7. pii: 6499977. doi: 10.1093.
    PubMed    


  144. SOFFIETTI R, Bettegowda C, Mellinghoff IK, Warren KE, et al
    Liquid biopsy in gliomas: a RANO review and proposals for clinical applications.
    Neuro Oncol. 2022 Jan 6. pii: 6499389. doi: 10.1093.
    PubMed     Abstract available


  145. MORTAZAVI A, Fayed I, Bachani M, Dowdy T, et al
    IDH Mutated Gliomas Promote Epileptogenesis through D-2-Hydroxyglutarate Dependent mTOR Hyperactivation.
    Neuro Oncol. 2022 Jan 5. pii: 6498134. doi: 10.1093.
    PubMed     Abstract available


  146. FURLAN JC, Wilson JR, Massicotte EM, Sahgal A, et al
    Recent advances and new discoveries in the pipeline of the treatment of primary spinal tumors and spinal metastases: a scoping review of registered clinical studies from 2000 to 2020.
    Neuro Oncol. 2022;24:1-13.
    PubMed     Abstract available


  147. JUHNKE BO, Gessi M, Gerber NU, Friedrich C, et al
    Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial.
    Neuro Oncol. 2022;24:127-137.
    PubMed     Abstract available


  148. LAMBA N, Catalano PJ, Bi WL, Wen PY, et al
    Predictors of long-term survival among patients with brain metastases.
    Neuro Oncol. 2022 Jan 4. pii: 6497420. doi: 10.1093.
    PubMed    


  149. KUNDU S, Nandhu MS, Longo SL, Longo JA, et al
    The scaffolding protein DLG5 promotes glioblastoma growth by controlling Sonic Hedgehog signaling in tumor stem cells.
    Neuro Oncol. 2022 Jan 4. pii: 6497518. doi: 10.1093.
    PubMed     Abstract available


  150. PAGES M, Rotem D, Gydush G, Reed S, et al
    Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine.
    Neuro Oncol. 2022 Jan 4. pii: 6497435. doi: 10.1093.
    PubMed     Abstract available


    December 2021
  151. DE BILLY E, Pellegrino M, Orlando D, Pericoli G, et al
    Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant.
    Neuro Oncol. 2021 Dec 29. pii: 6489024. doi: 10.1093.
    PubMed     Abstract available


  152. KNUDSEN AM, Halle B, Cedile O, Burton M, et al
    Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors.
    Neuro Oncol. 2021 Dec 29. pii: 6489042. doi: 10.1093.
    PubMed     Abstract available


  153. HU C, Wang K, Damon C, Fu Y, et al
    ATRX loss promotes immunosuppressive mechanisms in IDH1 mutant glioma.
    Neuro Oncol. 2021 Dec 24. pii: 6482823. doi: 10.1093.
    PubMed     Abstract available


  154. MEISSNER AK, Gutsche R, Galldiks N, Kocher M, et al
    Radiomics for the non-invasive prediction of the BRAF mutation status in patients with melanoma brain metastases.
    Neuro Oncol. 2021 Dec 22. pii: 6478897. doi: 10.1093.
    PubMed     Abstract available


  155. LEARY SES, Lindsay K, Geyer JR, Mehmet K, et al
    Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026).
    Neuro Oncol. 2021 Dec 22. pii: 6478443. doi: 10.1093.
    PubMed     Abstract available


  156. DESHPANDE K, Martirosian V, Nakamura BN, Iyer M, et al
    Neuronal exposure induces neurotransmitter signaling and synaptic mediators in tumors early in brain metastasis.
    Neuro Oncol. 2021 Dec 21. pii: 6473228. doi: 10.1093.
    PubMed     Abstract available


  157. YABO YA, Niclou SP, Golebiewska A
    Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma.
    Neuro Oncol. 2021 Dec 21. pii: 6472977. doi: 10.1093.
    PubMed     Abstract available


  158. GU J, Mu N, Jia B, Guo Q, et al
    Targeting radiation-tolerant persister cells as a strategy for inhibiting radioresistance and recurrence in glioblastoma.
    Neuro Oncol. 2021 Dec 14. pii: 6461092. doi: 10.1093.
    PubMed     Abstract available


  159. LUCAS JT, Tinkle CL, Huang J, Onar-Thomas A, et al
    Revised clinical and molecular risk strata define the incidence and pattern of failure in Medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study.
    Neuro Oncol. 2021 Dec 11. pii: 6459719. doi: 10.1093.
    PubMed     Abstract available


  160. LIM-FAT MJ, Youssef GC, Touat M, Iorgulescu JB, et al
    Clinical utility of targeted next generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making.
    Neuro Oncol. 2021 Dec 8. pii: 6456497. doi: 10.1093.
    PubMed     Abstract available


  161. GARZIA L
    Faraway, so close: intratumoral heterogeneity of medulloblastoma subgroups.
    Neuro Oncol. 2021 Dec 4. pii: 6449209. doi: 10.1093.
    PubMed    


  162. HAGIWARA A, Oughourlian TC, Cho NS, Schlossman J, et al
    Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.
    Neuro Oncol. 2021 Dec 2. pii: 6448328. doi: 10.1093.
    PubMed     Abstract available


  163. GUPTA T, Manjali JJ, Purandare N, Bagal B, et al
    Bone marrow biopsy in PCNSL: Relevant or redundant?
    Neuro Oncol. 2021;23:2117-2118.
    PubMed    


  164. MARGOLD M, Schlegel U
    Reply to letter to the editor by Gupta et al: Bone marrow biopsy in patients with PCNSL: relevant or redundant?
    Neuro Oncol. 2021;23:2119.
    PubMed    


  165. MOUDGIL-JOSHI J, Kaliaperumal C
    Letter regarding Louis et al: The 2021 WHO Classification of Tumors of the Central Nervous System: A summary.
    Neuro Oncol. 2021;23:2120-2121.
    PubMed    


  166. ECKEL-PASSOW JE, Kitange GJ, Decker PA, Kosel ML, et al
    Experimental design of preclinical experiments: number of PDX lines vs subsampling within PDX lines.
    Neuro Oncol. 2021;23:2066-2075.
    PubMed     Abstract available


  167. MARNER L, Lundemann M, Sehested A, Nysom K, et al
    Diagnostic accuracy and clinical impact of [18F]FET PET in childhood CNS tumors.
    Neuro Oncol. 2021;23:2107-2116.
    PubMed     Abstract available


    November 2021
  168. CHAREST A
    Optimizing an effective combination of the new microtubule targeting agent Lisavanbulin with standard of care therapy for glioblastoma in patient-derived xenograft pre-clinical models.
    Neuro Oncol. 2021 Nov 27. pii: 6444804. doi: 10.1093.
    PubMed    


  169. TAYLOR JW
    Treat the VTE and worry less about the hemorrhage: A sigh of relief or is the jury still out for therapeutic anticoagulation in high grade glioma?
    Neuro Oncol. 2021 Nov 27. pii: 6444703. doi: 10.1093.
    PubMed    


  170. LEMAITRE AL, Herbet G, Ng S, Moritz-Gasser S, et al
    Cognitive preservation following awake mapping-based neurosurgery for low-grade gliomas: a longitudinal, within-patient design study.
    Neuro Oncol. 2021 Nov 26. pii: 6444171. doi: 10.1093.
    PubMed     Abstract available


  171. ABDULLAH KG, Bird CE, Buehler JD, Gattie LC, et al
    Establishment of patient-derived organoid models of lower grade glioma.
    Neuro Oncol. 2021 Nov 26. pii: 6444299. doi: 10.1093.
    PubMed     Abstract available


  172. CHIOCCA EA, Gelb AB, Chen CC, Rao G, et al
    Combined immunotherapy with controlled Interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: an open-label, multi-institutional phase 1 trial.
    Neuro Oncol. 2021 Nov 26. pii: 6444298. doi: 10.1093.
    PubMed     Abstract available


  173. DA COSTA ROSA M, Yamashita AS, Riggins GJ
    Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas.
    Neuro Oncol. 2021 Nov 26. pii: 6440681. doi: 10.1093.
    PubMed     Abstract available


  174. DE JOODE K, Taal W, Snijders TJ, Hanse M, et al
    Patients with primary brain tumors and COVID-19: A report from the Dutch Oncology COVID-19 Consortium.
    Neuro Oncol. 2021 Nov 24. pii: 6437945. doi: 10.1093.
    PubMed    


  175. KIELISZEK AM, Aghaei N, Bassey-Archibong B, Singh SK, et al
    Low and steady wins the race: for melanoma-brain metastases, is prevention better than a cure?
    Neuro Oncol. 2021 Nov 24. pii: 6438512. doi: 10.1093.
    PubMed    


  176. WU J
    Targeting nicotinamide adenosine dinucleotide (NAD) in diffuse gliomas.
    Neuro Oncol. 2021 Nov 22. pii: 6433381. doi: 10.1093.
    PubMed    


  177. ALMSTEDT E, Rosen E, Gloger M, Stockgard R, et al
    Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts.
    Neuro Oncol. 2021 Nov 19. pii: 6432157. doi: 10.1093.
    PubMed     Abstract available


  178. NASSIRI F, Wang JZ, Au K, Barnholtz-Sloan J, et al
    Consensus core clinical data elements for meningiomas.
    Neuro Oncol. 2021 Nov 17. pii: 6430437. doi: 10.1093.
    PubMed     Abstract available


  179. BALIGA S, Gallotto S, Bajaj B, Lewy J, et al
    Decade Long Disease, Secondary Malignancy, and Brainstem Injury Outcomes in Pediatric and Young Adult Medulloblastoma Patients Treated with Proton Radiotherapy.
    Neuro Oncol. 2021 Nov 12. pii: 6425899. doi: 10.1093.
    PubMed     Abstract available


  180. KACHURI L, Walsh KM
    Long telomeres in need of a SNP: Germline contributions of telomere maintenance to glioma.
    Neuro Oncol. 2021 Nov 10. pii: 6425113. doi: 10.1093.
    PubMed    


  181. ELLINGSON BM, Kim GHJ, Brown M, Lee J, et al
    Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of Ivosidenib.
    Neuro Oncol. 2021 Nov 9. pii: 6424025. doi: 10.1093.
    PubMed     Abstract available


  182. ARAKAKI AKS, Szulzewsky F, Gilbert MR, Gujral TS, et al
    Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers.
    Neuro Oncol. 2021;23.
    PubMed     Abstract available


  183. PRATT D, Sahm F, Aldape K
    DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncology.
    Neuro Oncol. 2021;23.
    PubMed     Abstract available


  184. ARMSTRONG TS, Gilbert MR
    Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors.
    Neuro Oncol. 2021;23.
    PubMed     Abstract available


  185. PENAS-PRADO M
    Rare central nervous system tumors: the path to progress.
    Neuro Oncol. 2021;23.
    PubMed    


  186. ASA SL, Mete O
    Single-cell transcriptome and genome analysis: A much-needed tool for pituitary neuroendocrine tumor studies.
    Neuro Oncol. 2021;23:1803-1804.
    PubMed    


  187. CUI Y, Li C, Jiang Z, Zhang S, et al
    Single-cell transcriptome and genome analyses of pituitary neuroendocrine tumors.
    Neuro Oncol. 2021;23:1859-1871.
    PubMed     Abstract available


    October 2021
  188. MOLINARO AM
    External Controls to Improve on Glioblastoma Clinical Trials.
    Neuro Oncol. 2021 Oct 29. pii: 6414401. doi: 10.1093.
    PubMed    


  189. ANDREWS LJ, Thornton ZA, Saincher SS, Yao IY, et al
    Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review.
    Neuro Oncol. 2021 Oct 28. pii: 6413773. doi: 10.1093.
    PubMed     Abstract available


  190. SCHWARTZBAUM J, Harris R
    Age at diagnosis and sex interact to modify primary malignant glioma incidence and survival.
    Neuro Oncol. 2021 Oct 25. pii: 6409990. doi: 10.1093.
    PubMed    


  191. VACHHA BA, Huang RY
    BOLD Asynchrony: An imaging biomarker of tumor burden in IDH-mutated gliomas.
    Neuro Oncol. 2021 Oct 25. pii: 6409977. doi: 10.1093.
    PubMed    


  192. PREUSSER M, Silvani A, Le Rhun E, Soffietti R, et al
    Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG).
    Neuro Oncol. 2021 Oct 21. pii: 6406919. doi: 10.1093.
    PubMed     Abstract available


  193. BARRETTE AM, Ronk H, Joshi T, Mussa Z, et al
    Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor Verteporfin in preclinical glioblastoma models.
    Neuro Oncol. 2021 Oct 17. pii: 6398692. doi: 10.1093.
    PubMed     Abstract available


  194. CLUCERU J, Interian Y, Phillips JJ, Molinaro AM, et al
    Improving the noninvasive classification of glioma genetic subtype with deep learning and diffusion-weighted imaging.
    Neuro Oncol. 2021 Oct 15. pii: 6398212. doi: 10.1093.
    PubMed     Abstract available


  195. PANT A, Lim M
    Checkpoint blockade in recurrent meningiomas: Lessons for future management.
    Neuro Oncol. 2021 Oct 9. pii: 6385431. doi: 10.1093.
    PubMed    


  196. HOOGSTRATE Y, Ghisai SA, de Wit M, de Heer I, et al
    The EGFRvIII transcriptome in glioblastoma, a meta-omics analysis.
    Neuro Oncol. 2021 Oct 5. pii: 6381406. doi: 10.1093.
    PubMed     Abstract available


  197. STROWD RE
    Etched in Code: Revisiting glioma risk factors through the exome.
    Neuro Oncol. 2021 Oct 4. pii: 6380799. doi: 10.1093.
    PubMed    


  198. FRIEDMAN GK, Dhall G
    Potential Role of Carbon Ion Radiotherapy in Chromothripsis-induced Medulloblastoma and Other Malignancies.
    Neuro Oncol. 2021 Oct 4. pii: 6380754. doi: 10.1093.
    PubMed    


  199. WU J, Gupta R, Barreto J, Doo P, et al
    Tumor DNA requirements for accurate epigenetic-based classification of CNS neoplasia.
    Neuro Oncol. 2021;23:1798-1800.
    PubMed    


  200. PERTZ M, Schlegel U
    Tracking the neurobiology of cognitive dysfunction in primary CNS lymphoma?
    Neuro Oncol. 2021;23:1623-1624.
    PubMed    


  201. MILDE T, Rodriguez FJ, Barnholtz-Sloan JS, Patil N, et al
    Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas.
    Neuro Oncol. 2021;23:1634-1646.
    PubMed     Abstract available


  202. GENG H, Tsang M, Subbaraj L, Cleveland J, et al
    Tumor metabolism and neurocognition in CNS lymphoma.
    Neuro Oncol. 2021;23:1668-1679.
    PubMed     Abstract available


    September 2021
  203. DEL BENE M, Osti D, Faletti S, Beznousenko GV, et al
    Extracellular vesicles: the key for precision medicine in glioblastoma.
    Neuro Oncol. 2021 Sep 28. pii: 6377304. doi: 10.1093.
    PubMed     Abstract available


  204. RAO R, Han R, Ogurek S, Xue C, et al
    Glioblastoma Genetic Drivers Dictate the Function of Tumor-Associated Macrophages/Microglia and Responses to CSF1R Inhibition.
    Neuro Oncol. 2021 Sep 25. pii: 6375369. doi: 10.1093.
    PubMed     Abstract available


  205. PENG J, Kim DD, Patel JB, Zeng X, et al
    Corrigendum to: Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors.
    Neuro Oncol. 2021 Sep 22. pii: 6374130. doi: 10.1093.
    PubMed    


  206. JOSEPH JV, Magaut CR, Storevik S, Geraldo LH, et al
    TGF- promotes microtube formation in glioblastoma through Thrombospondin 1.
    Neuro Oncol. 2021 Sep 20. pii: 6372853. doi: 10.1093.
    PubMed     Abstract available


  207. LUCAS CG, Mueller S, Reddy A, Taylor JW, et al
    Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy.
    Neuro Oncol. 2021 Sep 14. pii: 6370137. doi: 10.1093.
    PubMed    


  208. WANG W, He H, Marin-Ramos NI, Zeng S, et al
    Corrigendum to: Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.
    Neuro Oncol. 2021 Sep 14. pii: 6370123. doi: 10.1093.
    PubMed    


  209. BORNHORST M
    New insights into low grade glioma tumor microenvironment for improved patient management.
    Neuro Oncol. 2021 Sep 13. pii: 6369407. doi: 10.1093.
    PubMed    


  210. ABOUNADER R, Schiff D
    The blood-brain barrier limits the therapeutic efficacy of antibody drug conjugates in glioblastoma.
    Neuro Oncol. 2021 Sep 13. pii: 6369406. doi: 10.1093.
    PubMed    


  211. ZHANG W, Talele S, Sarkaria JN, Elmquist WF, et al
    Changes in the vasculature of human brain tumors: Implications for treatment.
    Neuro Oncol. 2021 Sep 13. pii: 6369378. doi: 10.1093.
    PubMed    


  212. IJARE OB, Hambarde S, Brasil da Costa FH, Lopez S, et al
    Glutamine anaplerosis is required for amino acid biosynthesis in human meningiomas.
    Neuro Oncol. 2021 Sep 13. pii: 6369334. doi: 10.1093.
    PubMed     Abstract available


  213. MAROSI C
    Will mastering ferroptosis allow treating refractory meningiomas?
    Neuro Oncol. 2021 Sep 13. pii: 6369228. doi: 10.1093.
    PubMed    


  214. DRIVER J, Hoffman SE, Tavakol S, Woodward E, et al
    A Molecularly Integrated Grade for Meningioma.
    Neuro Oncol. 2021 Sep 11. pii: 6368844. doi: 10.1093.
    PubMed     Abstract available


  215. TOM MC, Kotecha R
    Beating a Benchmark: Boron Neutron Capture Therapy for Recurrent and Refractory Meningiomas.
    Neuro Oncol. 2021 Sep 11. pii: 6368846. doi: 10.1093.
    PubMed    


  216. IUS T, Ng S, Young JS, Tomasino B, et al
    The benefit of early surgery on overall survival in incidental low grade glioma patients: a multicenter study.
    Neuro Oncol. 2021 Sep 8. pii: 6366593. doi: 10.1093.
    PubMed     Abstract available


  217. SAUNDERS CN, Kinnersley B, Culliford R, Cornish AJ, et al
    Relationship between genetically determined telomere length and glioma risk.
    Neuro Oncol. 2021 Sep 3. pii: 6363706. doi: 10.1093.
    PubMed     Abstract available


  218. WANG D, Veo B, Pierce A, Fosmire S, et al
    A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
    Neuro Oncol. 2021 Sep 3. pii: 6363671. doi: 10.1093.
    PubMed     Abstract available


  219. BANDOPADHAYAY P, Chi SN
    The challenges in treating Embryonal Tumors with Multilayered Rosettes (ETMR) and other infant brain tumors.
    Neuro Oncol. 2021 Sep 3. pii: 6363655. doi: 10.1093.
    PubMed    


  220. AQUILANTI E, Kageler L, Wen PY, Meyerson M, et al
    Telomerase as a therapeutic target in glioblastoma.
    Neuro Oncol. 2021 Sep 2. pii: 6362724. doi: 10.1093.
    PubMed     Abstract available


  221. BRANDNER S, McAleenan A, Kelly C, Spiga F, et al
    MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
    Neuro Oncol. 2021;23:1457-1469.
    PubMed     Abstract available


  222. THACKER N, Bouffet E
    Posterior fossa syndrome-time to unmute the silence on cerebellar mutism.
    Neuro Oncol. 2021;23:1427-1428.
    PubMed    


  223. VON HOFF K, Haberler C, Schmitt-Hoffner F, Schepke E, et al
    Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study.
    Neuro Oncol. 2021;23:1597-1611.
    PubMed     Abstract available


  224. KHAN RB, Patay Z, Klimo P, Huang J, et al
    Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study.
    Neuro Oncol. 2021;23:1586-1596.
    PubMed     Abstract available


    August 2021
  225. CHUNG C, Brown PD, Wefel JS
    Short reply to "Proton therapy for newly diagnosed glioblastoma: More room for investigation" by R. Press et al.
    Neuro Oncol. 2021 Aug 28. pii: 6359127. doi: 10.1093.
    PubMed    


  226. PRESS RH, Chhabra AM, Choi JI, Hasan S, et al
    Proton therapy for newly diagnosed glioblastoma: more room for investigation.
    Neuro Oncol. 2021 Aug 28. pii: 6359128. doi: 10.1093.
    PubMed    


  227. CICONE F, Cascini GL, Minniti G
    Reply to: "Letter to the Editor: Assessment of imaging biomarkers in the follow-up of brain metastases after SRS".
    Neuro Oncol. 2021 Aug 24. pii: 6357080. doi: 10.1093.
    PubMed    


  228. DERKS SHAE, Jongen JLM, van den Bent MJ, van der Veldt AAM, et al
    Assessment of imaging biomarkers in the follow-up of brain metastases after SRS.
    Neuro Oncol. 2021 Aug 24. pii: 6357079. doi: 10.1093.
    PubMed    


  229. RONSLEY R, Bouffet E
    COVID-19 in pediatric cancer: Where are the brain tumors?
    Neuro Oncol. 2021 Aug 20. pii: 6355395. doi: 10.1093.
    PubMed    


  230. WANG GM, Cioffi G, Patil N, Waite KA, et al
    Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas.
    Neuro Oncol. 2021 Aug 13. pii: 6350590. doi: 10.1093.
    PubMed     Abstract available


  231. JO J, Donahue J, Sarai G, Petroni G, et al
    Management of Venous Thromboembolism in High-Grade Glioma: Does Low Molecular Weight Heparin Increase Intracranial Bleeding Risk?
    Neuro Oncol. 2021 Aug 12. pii: 6348905. doi: 10.1093.
    PubMed     Abstract available


  232. YANG WC, Chen YF, Yang CC, Wu PF, et al
    Erratum to: Hippocampal avoidance whole-brain radiotherapy without memantine in preserving neurocognitive function for brain metastases: a phase II blinded randomized trial.
    Neuro Oncol. 2021 Aug 7. pii: 6345198. doi: 10.1093.
    PubMed    


  233. LAMBA N, Aizer AA
    The evolving role of systemic therapy and local, brain-directed treatment in patients with melanoma and brain metastases.
    Neuro Oncol. 2021 Aug 5. pii: 6341089. doi: 10.1093.
    PubMed    


  234. WINKLER F
    Silencing glioblastoma networks to make temozolomide more effective.
    Neuro Oncol. 2021 Aug 4. pii: 6339977. doi: 10.1093.
    PubMed    


  235. SU JM, Kilburn LB, Mansur DB, Krailo M, et al
    Phase 1/2 Trial of Vorinostat and Radiation and Maintenance Vorinostat in Children with Diffuse Intrinsic Pontine Glioma: A Children's Oncology Group Report.
    Neuro Oncol. 2021 Aug 4. pii: 6339987. doi: 10.1093.
    PubMed     Abstract available


  236. HUANG H, Georganaki M, Conze LL, Lavina B, et al
    ELTD1-deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma.
    Neuro Oncol. 2021 Aug 4. pii: 6339962. doi: 10.1093.
    PubMed     Abstract available


  237. WEN PY, Packer RJ
    The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications.
    Neuro Oncol. 2021;23:1215-1217.
    PubMed    


  238. LOUIS DN, Perry A, Wesseling P, Brat DJ, et al
    The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
    Neuro Oncol. 2021;23:1231-1251.
    PubMed     Abstract available


  239. CORREA DD
    Neurocognitive functions in primary CNS lymphoma.
    Neuro Oncol. 2021;23:1220-1221.
    PubMed    


  240. MOSELLA MS, Sabedot TS, Silva TC, Malta TM, et al
    DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological features.
    Neuro Oncol. 2021;23:1292-1303.
    PubMed     Abstract available


  241. VAN DER MEULEN M, Dirven L, Habets EJJ, Bakunina K, et al
    Neurocognitive functioning and radiologic changes in primary CNS lymphoma patients: results from the HOVON 105/ALLG NHL 24 randomized controlled trial.
    Neuro Oncol. 2021;23:1315-1326.
    PubMed     Abstract available


    July 2021
  242. MUNOZ PINTO MF, Campbell SJ, Simoglou Karali C, Johanssen VA, et al
    Selective blood-brain barrier permeabilisation of brain metastases by a type-1 receptor selective tumour necrosis factor mutein.
    Neuro Oncol. 2021 Jul 23. pii: 6326734. doi: 10.1093.
    PubMed     Abstract available


  243. RICHARDSON S, Hill RM, Kui C, Lindsey JC, et al
    Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse.
    Neuro Oncol. 2021 Jul 17. pii: 6323243. doi: 10.1093.
    PubMed     Abstract available


  244. SHIH HA
    An early foray with targeted therapy and inspiring novel approaches to combat adult medulloblastoma.
    Neuro Oncol. 2021 Jul 16. pii: 6323026. doi: 10.1093.
    PubMed    


  245. HULSBERGEN AFC, Abunimer AM, Ida F, Kavouridis VK, et al
    Neurosurgical resection for locally recurrent brain metastasis.
    Neuro Oncol. 2021 Jul 16. pii: 6322695. doi: 10.1093.
    PubMed     Abstract available


  246. SHARMA P, Xu J, Williams K, Easley M, et al
    Inhibition of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the nicotinamide adenine dinucleotide salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
    Neuro Oncol. 2021 Jul 14. pii: 6321319. doi: 10.1093.
    PubMed     Abstract available


  247. LUDWIG N, Rao A, Sandlesh P, Yerneni SS, et al
    Characterization of systemic immunosuppression by IDH mutant glioma small extracellular vesicles.
    Neuro Oncol. 2021 Jul 13. pii: 6320007. doi: 10.1093.
    PubMed     Abstract available


  248. RAMASWAMY V, Bartels U
    Selumetinib for optic pathway glioma: Seeing through the fog, (not yet) the end of the tunnel?
    Neuro Oncol. 2021 Jul 12. pii: 6319139. doi: 10.1093.
    PubMed    


  249. BALANA C, Sun C, Vaz MA, Esteve A, et al
    Reply to: Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
    Neuro Oncol. 2021 Jul 9. pii: 6318238. doi: 10.1093.
    PubMed    


  250. TERABE M, Wu J
    Rethinking Immunotherapy in Meningiomas.
    Neuro Oncol. 2021 Jul 9. pii: 6318447. doi: 10.1093.
    PubMed    


  251. ZHAO B, Ma W
    Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?
    Neuro Oncol. 2021 Jul 9. pii: 6318242. doi: 10.1093.
    PubMed    


  252. BAGLEY SJ, Kline CN
    Understanding the global impact of primary brain tumors: the untapped potential of population-based cancer registries.
    Neuro Oncol. 2021 Jul 9. pii: 6318451. doi: 10.1093.
    PubMed    


  253. LUKAS RV
    Essential Oils for Blood-Brain Barrier Disruption: Preclinical Studies of NEO100 in Breast Cancer Brain Metastases.
    Neuro Oncol. 2021 Jul 9. pii: 6318449. doi: 10.1093.
    PubMed    


  254. ALHALABI OT, Fletcher MNC, Hielscher T, Kessler T, et al
    A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma.
    Neuro Oncol. 2021 Jul 7. pii: 6316731. doi: 10.1093.
    PubMed     Abstract available


  255. TONOGAI EJ, Huang S, Botham RC, Berry MR, et al
    Evaluation of a procaspase-3 activator with hydroxyurea or temozolomide against high-grade meningioma in cell culture and canine cancer patients.
    Neuro Oncol. 2021 Jul 3. pii: 6314291. doi: 10.1093.
    PubMed     Abstract available


  256. TEHRANIAN C, Fankhauser L, Harter PN, Ratcliffe CDH, et al
    The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis.
    Neuro Oncol. 2021 Jul 3. pii: 6314211. doi: 10.1093.
    PubMed     Abstract available


  257. PETRIDIS PD, Horenstein C, Pereira B, Wu P, et al
    BOLD Asynchrony Elucidates Tumor Burden in IDH-Mutated Gliomas.
    Neuro Oncol. 2021 Jul 2. pii: 6313213. doi: 10.1093.
    PubMed     Abstract available


  258. YAMAZAKI S, Ohka F, Hirano M, Shiraki Y, et al
    Newly Established Patient-derived Organoid Model of Intracranial Meningioma.
    Neuro Oncol. 2021 Jul 2. pii: 6313216. doi: 10.1093.
    PubMed     Abstract available


  259. D'ALESSANDRIS QG, Della Pepa GM, Noya C, Olivi A, et al
    Mesenchymal stem cells: are they the good or the bad?
    Neuro Oncol. 2021;23:1203-1204.
    PubMed    


  260. DANKNER M, Maritan SM
    The relevance of surgical status in nodular leptomeningeal metastasis patient outcomes.
    Neuro Oncol. 2021;23:1207.
    PubMed    


  261. LE RHUN E, Devos P, Weller J, Seystahl K, et al
    Prognostic factors in leptomeningeal metastases.
    Neuro Oncol. 2021;23:1208-1209.
    PubMed    


  262. BARAJAS RF, Politi LS, Anzalone N, Schoder H, et al
    Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG).
    Neuro Oncol. 2021;23:1056-1071.
    PubMed     Abstract available


  263. LE RHUN E, Devos P, Weller J, Seystahl K, et al
    Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors.
    Neuro Oncol. 2021;23:1100-1112.
    PubMed     Abstract available


  264. FORDE C, King AT, Rutherford SA, Hammerbeck-Ward C, et al
    Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution.
    Neuro Oncol. 2021;23:1113-1124.
    PubMed     Abstract available


    June 2021
  265. GOLDBRUNNER R, Stavrinou P, Jenkinson MD, Sahm F, et al
    EANO guideline on the diagnosis and management of meningiomas.
    Neuro Oncol. 2021 Jun 28. pii: 6310843. doi: 10.1093.
    PubMed     Abstract available


  266. WALBERT T, Harrison RA, Schiff D, Avila EK, et al
    SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors.
    Neuro Oncol. 2021 Jun 26. pii: 6310125. doi: 10.1093.
    PubMed     Abstract available


  267. PENG J, Kim DD, Patel JB, Zeng X, et al
    Deep Learning-Based Automatic Tumor Burden Assessment of Pediatric High-Grade Gliomas, Medulloblastomas, and Other Leptomeningeal Seeding Tumors.
    Neuro Oncol. 2021 Jun 26. pii: 6310123. doi: 10.1093.
    PubMed     Abstract available


  268. WIRSCHING HG, Steiner L, Becker D, Regli L, et al
    Increase in contrast-enhancing volume of irradiated meningiomas reflects tumor progression and not pseudoprogression.
    Neuro Oncol. 2021 Jun 19. pii: 6305986. doi: 10.1093.
    PubMed    


  269. JOHNSON KC, Verhaak RGW
    Serum cell-free DNA epigenetic biomarkers aid glioma diagnostics and monitoring.
    Neuro Oncol. 2021 Jun 17. pii: 6302547. doi: 10.1093.
    PubMed    


  270. HAU P
    Dissecting adult SHH-activated medulloblastoma - molecularly defined tumor subsets reveal new prognostic biomarkers.
    Neuro Oncol. 2021 Jun 17. pii: 6302543. doi: 10.1093.
    PubMed    


  271. SHAH AH, Gilbert M, Ivan ME, Komotar RJ, et al
    The role of human endogenous retroviruses in gliomas: from etiological perspectives and therapeutic implications.
    Neuro Oncol. 2021 Jun 12. pii: 6297568. doi: 10.1093.
    PubMed     Abstract available


  272. ERKER C, Lane A, Chaney B, Leary S, et al
    Characteristics of Patients >/= 10 Years of Age with Diffuse Intrinsic Pontine Glioma: A Report from the International DIPG Registry.
    Neuro Oncol. 2021 Jun 11. pii: 6296498. doi: 10.1093.
    PubMed     Abstract available


  273. SHEEHAN J, Pikis S, Islim A, Chen CJ, et al
    An International Multicenter Matched Cohort Analysis of Incidental Meningioma Progression During Active Surveillance or After Stereotactic Radiosurgery: The IMPASSE Study.
    Neuro Oncol. 2021 Jun 9. pii: 6295369. doi: 10.1093.
    PubMed     Abstract available


  274. KOTECHA R, Aboian M, Nabavizadeh SA, Parent EE, et al
    Letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation.
    Neuro Oncol. 2021 Jun 3. pii: 6291736. doi: 10.1093.
    PubMed    


  275. GALLDIKS N, Niyazi M, Tonn JC, Langen KJ, et al
    Reply to the letter regarding "Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients-a report of the PET/RANO group": 18F-fluciclovine and target volume delineation.
    Neuro Oncol. 2021 Jun 3. pii: 6291737. doi: 10.1093.
    PubMed    


  276. RIEMONDY KA, Venkataraman S, Willard N, Nellan A, et al
    Neoplastic and immune single cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma.
    Neuro Oncol. 2021 Jun 2. pii: 6291352. doi: 10.1093.
    PubMed     Abstract available


  277. RITZMANN TA, Kilday JP, Grundy RG
    Pediatric ependymomas: destined to recur?
    Neuro Oncol. 2021;23:874-876.
    PubMed    


  278. POON MTC, Brennan PM, Jin K, Sudlow CLM, et al
    Might changes in diagnostic practice explain increasing incidence of brain and central nervous system tumors? A population-based study in Wales (United Kingdom) and the United States.
    Neuro Oncol. 2021;23:979-989.
    PubMed     Abstract available


  279. ADOLPH JE, Fleischhack G, Mikasch R, Zeller J, et al
    Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study.
    Neuro Oncol. 2021;23:1012-1023.
    PubMed     Abstract available


    May 2021
  280. PHILLIPS LM, Li S, Gumin J, Daou M, et al
    An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus.
    Neuro Oncol. 2021 May 31. pii: 6290257. doi: 10.1093.
    PubMed     Abstract available


  281. MARIN BM, Porath KA, Jain S, Kim M, et al
    Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.
    Neuro Oncol. 2021 May 29. pii: 6288409. doi: 10.1093.
    PubMed     Abstract available


  282. SCOCCIANTI S, Olmetto E, Pinzi V, Osti MF, et al
    Immunotherapy in association with stereotactic radiotherapy for Non-Small Cell Lung Cancer brain metastases: results from a multicentric retrospective study on behalf of AIRO.
    Neuro Oncol. 2021 May 29. pii: 6288399. doi: 10.1093.
    PubMed     Abstract available


  283. VERBURG N, Barthel FP, Anderson KJ, Johnson KC, et al
    Spatial concordance of DNA methylation classification in diffuse glioma.
    Neuro Oncol. 2021 May 28. pii: 6287958. doi: 10.1093.
    PubMed     Abstract available


  284. SIMOVIC M, Bolkestein M, Moustafa M, Wong JKL, et al
    Carbon ion radiotherapy eradicates medulloblastomas with chromothripsis in an orthotopic Li-Fraumeni patient-derived mouse model.
    Neuro Oncol. 2021 May 28. pii: 6287957. doi: 10.1093.
    PubMed     Abstract available


  285. DE ANDRADE COSTA A, Chatterjee J, Cobb O, Sanapala S, et al
    RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth.
    Neuro Oncol. 2021 May 27. pii: 6286081. doi: 10.1093.
    PubMed     Abstract available


  286. LI Y, Wang X, Qi S, Gao L, et al
    Spliceosome-regulated RSRP1-dependent NF-kappaB activation promotes the glioblastoma mesenchymal phenotype.
    Neuro Oncol. 2021 May 27. pii: 6286882. doi: 10.1093.
    PubMed     Abstract available


  287. LAPERRIERE NJ
    Protons for the Management of Adult Patients with Glioblastoma.
    Neuro Oncol. 2021 May 24. pii: 6283746. doi: 10.1093.
    PubMed    


  288. MENDOZA TR
    Especially for neuro-oncologists - minimally important differences for the EORTC QLQ-C30 in glioma patients.
    Neuro Oncol. 2021 May 24. pii: 6283743. doi: 10.1093.
    PubMed    


  289. CHONGSATHIDKIET P, Fecci PE
    Cold-inducible RNA-binding protein (CIRBP) as a biomarker to predict recurrence of brain metastases.
    Neuro Oncol. 2021 May 24. pii: 6283744. doi: 10.1093.
    PubMed    


  290. BI WL, Nayak L, Meredith DM, Driver J, et al
    Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results.
    Neuro Oncol. 2021 May 20. pii: 6279078. doi: 10.1093.
    PubMed     Abstract available


  291. GUSYATINER O, Bady P, Pham MDT, Lei Y, et al
    BET inhibitors repress expression of Interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma.
    Neuro Oncol. 2021 May 14. pii: 6275457. doi: 10.1093.
    PubMed     Abstract available


  292. SIM HW, McDonald KL, Lwin Z, Barnes EH, et al
    A randomized phase II trial of veliparib, radiotherapy and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
    Neuro Oncol. 2021 May 13. pii: 6275307. doi: 10.1093.
    PubMed     Abstract available


  293. DAHL NA, Vibhakar R
    Converging evidence for inhibition of transcriptional control in high-grade gliomas.
    Neuro Oncol. 2021 May 13. pii: 6275360. doi: 10.1093.
    PubMed    


  294. TAKAI S, Wanibuchi M, Kawabata S, Takeuchi K, et al
    Reactor-based boron neutron capture therapy for 44 cases of recurrent and refractory high-grade meningiomas with long-term follow-up.
    Neuro Oncol. 2021 May 13. pii: 6275296. doi: 10.1093.
    PubMed     Abstract available


  295. BAO Z, Hua L, Ye Y, Wang D, et al
    MEF2C silencing downregulates NF2 and E-cadherin and enhances Erastin-induced ferroptosis in meningioma.
    Neuro Oncol. 2021 May 13. pii: 6275374. doi: 10.1093.
    PubMed     Abstract available


  296. WANG Z, Gao L, Wang Y, Chang M, et al
    Validation of the prognostic value of 9-gene ATE score for IDH wild-type glioblastoma.
    Neuro Oncol. 2021 May 13. pii: 6275034. doi: 10.1093.
    PubMed    


  297. NASSIRI F, Wang JZ, Singh O, Karimi S, et al
    Loss of H3K27me3 in meningiomas.
    Neuro Oncol. 2021 May 10. pii: 6273127. doi: 10.1093.
    PubMed     Abstract available


  298. FELKER J, Agnihotri S
    Not all mouse blood-brain barriers are created equal.
    Neuro Oncol. 2021;23:705-706.
    PubMed    


  299. SO J, Mamatjan Y, Zadeh G, Aldape K, et al
    Transcription factor networks of oligodendrogliomas treated with adjuvant radiotherapy or observation inform prognosis.
    Neuro Oncol. 2021;23:795-802.
    PubMed     Abstract available


  300. MASSIMINO M, Barretta F, Modena P, Witt H, et al
    Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up.
    Neuro Oncol. 2021;23:848-857.
    PubMed     Abstract available


  301. CLAUS EB, Cannataro VL, Gaffney SG, Townsend JP, et al
    Environmental and sex-specific molecular signatures of glioma causation.
    Neuro Oncol. 2021 May 4. pii: 6263733. doi: 10.1093.
    PubMed     Abstract available


    April 2021
  302. BRANDNER S, McAleenan A, Kelly C, Spiga F, et al
    MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Review.
    Neuro Oncol. 2021 Apr 30. pii: 6263562. doi: 10.1093.
    PubMed     Abstract available


  303. YEUNG J, Yaghoobi V, Miyagishima D, Vesely MD, et al
    Targeting the CSF1/CSF1R Axis is a Potential Treatment Strategy for Malignant Meningiomas.
    Neuro Oncol. 2021 Apr 29. pii: 6259024. doi: 10.1093.
    PubMed     Abstract available


  304. TESILEANU CMS, van den Bent MJ, Sanson M, Wick W, et al
    Prognostic significance of genome-wide DNA methylation profiles within the randomised, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.
    Neuro Oncol. 2021 Apr 29. pii: 6259004. doi: 10.1093.
    PubMed     Abstract available


  305. LAMBA N, Wen PY, Aizer AA
    Epidemiology of Brain Metastases and Leptomeningeal Disease.
    Neuro Oncol. 2021 Apr 28. pii: 6256866. doi: 10.1093.
    PubMed     Abstract available


  306. STROTHER D, Lafay-Cousin L
    Adjuvant therapy for high risk medulloblastoma: More is better?
    Neuro Oncol. 2021 Apr 27. pii: 6254485. doi: 10.1093.
    PubMed    


  307. MARINELLI JP, Carlson ML
    Potential for selection bias surrounding reporting of benign brain tumors in the United States.
    Neuro Oncol. 2021 Apr 26. pii: 6253739. doi: 10.1093.
    PubMed    


  308. TAWBI HA, Forsyth PA, Hodi FS, Lao CD, et al
    Safety and Efficacy of the Combination of Nivolumab Plus Ipilimumab in Patients With Melanoma and Asymptomatic or Symptomatic Brain Metastases (CheckMate 204).
    Neuro Oncol. 2021 Apr 21. pii: 6242717. doi: 10.1093.
    PubMed     Abstract available


  309. NICLOU SP, Golebiewska A
    Turning strength into weakness: protein degradation and autophagy as therapeutic targets in Glioblastoma?
    Neuro Oncol. 2021 Apr 17. pii: 6231737. doi: 10.1093.
    PubMed    


  310. SCHNEIDER M, Vollmer L, Potthoff AL, Ravi VM, et al
    Meclofenamate causes loss of cellular tethering and decoupling of functional networks in glioblastoma.
    Neuro Oncol. 2021 Apr 17. pii: 6231712. doi: 10.1093.
    PubMed     Abstract available


  311. VISWANATH P, Batsios G, Ayyappan V, Taglang C, et al
    Metabolic imaging detects elevated glucose flux through the pentose phosphate pathway associated with TERT expression in low-grade gliomas.
    Neuro Oncol. 2021 Apr 17. pii: 6231711. doi: 10.1093.
    PubMed     Abstract available


  312. VOLMAR MNM, Cheng J, Alenezi H, Richter S, et al
    Cannabidiol converts NFkappaB into a tumor suppressor in glioblastoma with defined antioxidative properties.
    Neuro Oncol. 2021 Apr 17. pii: 6231710. doi: 10.1093.
    PubMed     Abstract available


  313. KATSUSHIMA K, Lee B, Kunhiraman H, Zhong C, et al
    The long noncoding RNA lnc-HLX-2-7 is oncogenic in Group 3 medulloblastomas.
    Neuro Oncol. 2021;23:572-585.
    PubMed     Abstract available


  314. THOMAS C, Soschinski P, Zwaig M, Oikonomopoulos S, et al
    The genetic landscape of choroid plexus tumors in children and adults.
    Neuro Oncol. 2021;23:650-660.
    PubMed     Abstract available


  315. WANIS HA, Moller H, Ashkan K, Davies EA, et al
    The incidence of major subtypes of primary brain tumours in adults in England 1995-2017.
    Neuro Oncol. 2021 Apr 9. pii: 6218679. doi: 10.1093.
    PubMed     Abstract available


  316. HORBINSKI C, McCortney K, Stupp R
    MGMT promoter methylation is associated with patient age and 1p/19q status in IDH-mutant gliomas.
    Neuro Oncol. 2021 Apr 8. pii: 6217333. doi: 10.1093.
    PubMed    


  317. MUKHERJEE S, Schiltz G, Clutter M, Mishra R, et al
    Erratum to: DDIS-27. TARGETING ATP DOCKING AND P35/P25 BINDING OF CDK5 IN GLIOMA STEM CELLS USING SYNTHETIC INHIBITORS.
    Neuro Oncol. 2021 Apr 7. pii: 6214067. doi: 10.1093.
    PubMed    


  318. MUKHERJEE S, Olson C, Dundar B, Sharma N, et al
    Erratum to: STEM-19. RESISTANCE IS FUTILE: UNDERSTANDING AND TARGETING THE CDK5-CREB1-MCL1 AXIS TO PREVENT RADIATION RESISTANCE IN GLIOMA STEM CELLS.
    Neuro Oncol. 2021 Apr 7. pii: 6214066. doi: 10.1093.
    PubMed    


  319. FRAPPAZ D, Barritault M, Montane L, Laigle-Donadey F, et al
    MEVITEM - A Phase I/II of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
    Neuro Oncol. 2021 Apr 7. pii: 6213882. doi: 10.1093.
    PubMed     Abstract available


  320. YU Y, Villanueva-Meyer J, Grimmer MR, Hilz S, et al
    Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas.
    Neuro Oncol. 2021 Apr 5. pii: 6211336. doi: 10.1093.
    PubMed     Abstract available


  321. SANTAGATA S, Ligon KL
    Prognostication for meningiomas: H3K27me3 to the rescue?
    Neuro Oncol. 2021 Apr 3. pii: 6209863. doi: 10.1093.
    PubMed    


  322. TSANG DS, Schulte F
    Beyond the brain: Socioeconomic status and race in pediatric brain tumor survivorship.
    Neuro Oncol. 2021 Apr 3. pii: 6209877. doi: 10.1093.
    PubMed    


  323. LEE EQ, Selig W, Meehan C, Bacha J, et al
    Report of National Brain Tumor Society Roundtable Workshop on Innovating Brain Tumor Clinical Trials: Building on Lessons Learned from COVID-19 Experience.
    Neuro Oncol. 2021 Apr 2. pii: 6209406. doi: 10.1093.
    PubMed     Abstract available


    March 2021
  324. PERKINS S, Acharya S
    Radiation therapy to the developing brain: advanced technology is ready for robust optimization parameters.
    Neuro Oncol. 2021;23:350-351.
    PubMed    


  325. LASSMAN AB, Cloughesy TF
    Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?
    Neuro Oncol. 2021;23:347-349.
    PubMed    


  326. KUMTHEKAR P, Dunbar EM, Peters KB, Brastianos PK, et al
    A broad perspective on evaluating bias in the neuro-oncology workplace.
    Neuro Oncol. 2021;23:498-499.
    PubMed    


  327. GILBERT MR, Yuan Y, Wu J, Mendoza T, et al
    A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma.
    Neuro Oncol. 2021;23:468-477.
    PubMed     Abstract available


  328. JAECKLE KA, Ballman KV, van den Bent M, Giannini C, et al
    CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design.
    Neuro Oncol. 2021;23:457-467.
    PubMed     Abstract available


  329. BOURDEAUT F
    Are B7-H3 CAR-T cells the future universal treatment for pediatric brain tumors?
    Neuro Oncol. 2021 Mar 23. pii: 6182498. doi: 10.1093.
    PubMed    


  330. LU SL, Xiao FR, Cheng JC, Yang WC, et al
    Randomized Multi-Reader Evaluation of Automated Detection and Segmentation of Brain Tumors in Stereotactic Radiosurgery with Deep Neural Networks.
    Neuro Oncol. 2021 Mar 23. pii: 6180141. doi: 10.1093.
    PubMed     Abstract available


  331. LATHIA JD
    Fountain of chaos: cerebrospinal fluid enhancement of cancer stem cells in glioblastoma.
    Neuro Oncol. 2021 Mar 22. pii: 6179836. doi: 10.1093.
    PubMed    


  332. NOBRE L, Ramaswamy V
    Medulloblastoma (cross)talk through extracellular vesicles.
    Neuro Oncol. 2021 Mar 22. pii: 6179837. doi: 10.1093.
    PubMed    


  333. OSTROM QT, Edelson J, Byun J, Han Y, et al
    Partitioned glioma heritability shows subtype-specific enrichment in immune cells.
    Neuro Oncol. 2021 Mar 20. pii: 6179266. doi: 10.1093.
    PubMed     Abstract available


  334. GIRARDI F, Rous B, Stiller CA, Gatta G, et al
    The histology of brain tumours for 67,331 children and 671,085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3).
    Neuro Oncol. 2021 Mar 19. pii: 6178525. doi: 10.1093.
    PubMed     Abstract available


  335. VERKOUTEREN BJA, Cosgun B, Vermeulen RJ, Reinders MGHC, et al
    Prevalence of medulloblastoma in basal cell nevus syndrome patients with a PTCH1 mutation.
    Neuro Oncol. 2021 Mar 17. pii: 6231902. doi: 10.1093.
    PubMed    


  336. TSIEN C
    Stereotactic radiation therapy with concurrent immunotherapy for recurrent glioblastoma-hope or hype?
    Neuro Oncol. 2021 Mar 12. pii: 6168946. doi: 10.1093.
    PubMed    


  337. WINKLER F
    In glioma, all endothelial cells are not created the same.
    Neuro Oncol. 2021 Mar 11. pii: 6168415. doi: 10.1093.
    PubMed    


  338. SAIT SF, Karajannis MA
    Pediatric spinal cord gliomas - low grade but high risk for recurrence: should we treat them differently from intracranial low-grade gliomas?
    Neuro Oncol. 2021 Mar 11. pii: 6168346. doi: 10.1093.
    PubMed    


  339. TRIFILETTI DM, Brown PD
    Cognitive outcomes in patients with low-grade glioma.
    Neuro Oncol. 2021 Mar 11. pii: 6168225. doi: 10.1093.
    PubMed    


  340. FONSECA A, Bouffet E
    Brainstem Gliomas... The Devil is in the Details.
    Neuro Oncol. 2021 Mar 11. pii: 6168340. doi: 10.1093.
    PubMed    


  341. BAUMERT BG, Pesce GA
    Elderly patients with brain metastases: new support for the balancing act in treatment decision making.
    Neuro Oncol. 2021 Mar 11. pii: 6168221. doi: 10.1093.
    PubMed    


  342. MENG Y, Pople CB, Suppiah S, Llinas M, et al
    MR-guided focused ultrasound liquid biopsy enriches circulating biomarkers in patients with brain tumors.
    Neuro Oncol. 2021 Mar 10. pii: 6167330. doi: 10.1093.
    PubMed     Abstract available


  343. LIM-FAT MJ, Maralani PJ
    Is there an optimal MRI surveillance schedule for patients with high grade glioma after standard of care therapy?
    Neuro Oncol. 2021 Mar 1. pii: 6155531. doi: 10.1093.
    PubMed    


  344. SPERDUTO PW, Lou E
    The Past, Current and Future Management of Brain Metastases in EGFR-Mutant Non-Small Cell Lung Cancer.
    Neuro Oncol. 2021 Mar 1. pii: 6155599. doi: 10.1093.
    PubMed    


    February 2021
  345. GIANNINI C, Giangaspero F
    TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH-wildtype glioblastoma?
    Neuro Oncol. 2021 Feb 28. pii: 6154503. doi: 10.1093.
    PubMed    


  346. WANG W, He H, Marin-Ramos NI, Zeng S, et al
    Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer.
    Neuro Oncol. 2021 Feb 28. pii: 6154448. doi: 10.1093.
    PubMed     Abstract available


  347. BROWN PD, Chung C, Liu DD, McAvoy S, et al
    A Prospective Phase II Randomized Trial of Proton Radiotherapy vs. Intensity Modulated Radiotherapy for Patients with Newly Diagnosed Glioblastoma.
    Neuro Oncol. 2021 Feb 27. pii: 6154000. doi: 10.1093.
    PubMed     Abstract available


  348. JESSURUN CAC, Hulsbergen AFC, de Wit AE, Tewarie IA, et al
    The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis.
    Neuro Oncol. 2021 Feb 25. pii: 6150018. doi: 10.1093.
    PubMed     Abstract available


  349. FANGUSARO J, Onar-Thomas A, Poussaint TY, Wu S, et al
    A Phase 2 Trial of Selumetinib in Children with Recurrent Optic Pathway and Hypothalamic Low-Grade Glioma without NF1: A Pediatric Brain Tumor Consortium Study.
    Neuro Oncol. 2021 Feb 25. pii: 6149924. doi: 10.1093.
    PubMed     Abstract available


  350. TSCHERNICHOVSKY R, Katz LH, Derazne E, Berliner MB, et al
    Height in Adolescence as a Risk Factor for Glioma Subtypes: a Nationwide Retrospective Cohort Study of 2.2 Million Subjects.
    Neuro Oncol. 2021 Feb 25. pii: 6149925. doi: 10.1093.
    PubMed     Abstract available


  351. JAIN R, Chi AS
    Radiogenomics identifying important biological pathways in gliomas.
    Neuro Oncol. 2021;23:177-178.
    PubMed    


  352. ELLINGSON BM, Brown MS, Boxerman JL, Gerstner ER, et al
    Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials.
    Neuro Oncol. 2021;23:189-198.
    PubMed     Abstract available


  353. KANAMORI M, Takami H, Yamaguchi S, Sasayama T, et al
    So-called bifocal tumors with diabetes insipidus and negative tumor markers: are they all germinoma?
    Neuro Oncol. 2021;23:295-303.
    PubMed     Abstract available


  354. CANNON-ALBRIGHT LA, Farnham JM, Stevens J, Teerlink CC, et al
    Genome-wide analysis of high-risk primary brain cancer pedigrees identifies PDXDC1 as a candidate brain cancer predisposition gene.
    Neuro Oncol. 2021;23:277-283.
    PubMed     Abstract available


  355. MATHEN P, Smart DK
    Reimagining External Beam Radiotherapy for Glioblastoma: "Old Beam, New Trick".
    Neuro Oncol. 2021 Feb 22. pii: 6146614. doi: 10.1093.
    PubMed    


  356. KIM MM, Aryal MP, Sun Y, Parmar HA, et al
    Response assessment during chemoradiation using a hypercellular/hyperperfused imaging phenotype predicts survival in patients with newly diagnosed glioblastoma.
    Neuro Oncol. 2021 Feb 18. pii: 6144576. doi: 10.1093.
    PubMed     Abstract available


  357. DIRVEN L, Musoro JZ, Coens C, Reijneveld JC, et al
    Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients.
    Neuro Oncol. 2021 Feb 18. pii: 6142946. doi: 10.1093.
    PubMed     Abstract available


  358. KORSHUNOV A, Okonechnikov K, Stichel D, Ryzhova M, et al
    Integrated molecular analysis of adult Sonic Hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator.
    Neuro Oncol. 2021 Feb 16. pii: 6137557. doi: 10.1093.
    PubMed     Abstract available


  359. HUANG T, Cheng SY
    Targeting phospholipid metabolism for glioblastoma therapy.
    Neuro Oncol. 2021 Feb 9. pii: 6131652. doi: 10.1093.
    PubMed    


  360. SCHAFFENRATH J, Wyss T, He L, Rushing EJ, et al
    Blood-brain barrier alterations in human brain tumors revealed by genome-wide transcriptomic profiling.
    Neuro Oncol. 2021 Feb 9. pii: 6131739. doi: 10.1093.
    PubMed     Abstract available


  361. SABEDOT T, Malta T, Snyder J, Nelson K, et al
    A serum-based DNA methylation assay provides accurate detection of glioma.
    Neuro Oncol. 2021 Feb 9. pii: 6131768. doi: 10.1093.
    PubMed     Abstract available


  362. GRAILLON T, Ferrer L, Siffre J, Sanson M, et al
    Role of 3-D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study.
    Neuro Oncol. 2021 Feb 8. pii: 6131353. doi: 10.1093.
    PubMed     Abstract available


  363. GUO X, Wang S, Wang Y, Ma W, et al
    Anti-PD-1 plus anti-VEGF therapy in multiple intracranial metastases of a hypermutated, IDH wild-type glioblastoma.
    Neuro Oncol. 2021 Feb 8. pii: 6131355. doi: 10.1093.
    PubMed    


  364. YAMAMOTO M, Sanomachi T, Suzuki S, Uchida H, et al
    Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma.
    Neuro Oncol. 2021 Feb 8. pii: 6131352. doi: 10.1093.
    PubMed     Abstract available


  365. OTANI Y, Sur H, Rachaiah G, Namagiri S, et al
    Inhibiting protein phosphatase 2A increases the antitumor effect of protein arginine methyltransferase 5 inhibition in models of glioblastoma.
    Neuro Oncol. 2021 Feb 8. pii: 6131351. doi: 10.1093.
    PubMed     Abstract available


  366. TORRES VA, Ashford JM, Wright E, Xu J, et al
    The Impact of Socioeconomic Status (SES) on Cognitive Outcomes Following Radiotherapy for Pediatric Brain Tumors: A Prospective, Longitudinal Trial.
    Neuro Oncol. 2021 Feb 5. pii: 6128895. doi: 10.1093.
    PubMed     Abstract available


  367. LIAO Y, Luo Z, Deng Y, Zhang F, et al
    OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes.
    Neuro Oncol. 2021 Feb 4. pii: 6128721. doi: 10.1093.
    PubMed     Abstract available


  368. GALLDIKS N, Niyazi M, Grosu AL, Kocher M, et al
    Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group.
    Neuro Oncol. 2021 Feb 4. pii: 6128548. doi: 10.1093.
    PubMed     Abstract available


    January 2021
  369. WEFEL JS, Armstrong TS, Pugh SL, Gilbert MR, et al
    Neurocognitive, Symptom, and Health- Related Quality of Life Outcomes of a Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma (NRG/RTOG 0825).
    Neuro Oncol. 2021 Jan 30. pii: 6124000. doi: 10.1093.
    PubMed     Abstract available


  370. YANG TJ, Wijetunga NA, Yamada J, Wolden S, et al
    Clinical trial of proton craniospinal irradiation for leptomeningeal metastases.
    Neuro Oncol. 2021;23:134-143.
    PubMed     Abstract available


  371. NARITA Y, Nagane M, Mishima K, Terui Y, et al
    Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
    Neuro Oncol. 2021;23:122-133.
    PubMed     Abstract available


  372. MAIRE CL, Fuh MM, Kaulich K, Fita KD, et al
    Genome-wide methylation profiling of glioblastoma cell-derived extracellular vesicle DNA allows tumor classification.
    Neuro Oncol. 2021 Jan 28. pii: 6122789. doi: 10.1093.
    PubMed     Abstract available


  373. GERRITSEN JKW, Vincent AJPE, De Vleeschouwer S
    Maximizing extent of resection while minimizing the risk of neurological morbidity in glioma patients: a novel grading scale to translate these surgical goals into a merged onco-functional clinical outcome.
    Neuro Oncol. 2021 Jan 20. pii: 6104892. doi: 10.1093.
    PubMed    


  374. VARGAS LOPEZ AJ
    Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
    Neuro Oncol. 2021 Jan 20. pii: 6104916. doi: 10.1093.
    PubMed    


  375. DIAMANDIS P
    De-coding group 3 medulloblastoma biology with non-coding RNA.
    Neuro Oncol. 2021 Jan 20. pii: 6104902. doi: 10.1093.
    PubMed    


  376. KATAGI H, Takata N, Aoi Y, Zhang Y, et al
    Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
    Neuro Oncol. 2021 Jan 20. pii: 6104638. doi: 10.1093.
    PubMed     Abstract available


  377. WEN PY, Weller M, Chiocca EA, Lim M, et al
    Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez.
    Neuro Oncol. 2021 Jan 20. pii: 6104896. doi: 10.1093.
    PubMed    


  378. FULTS DW
    Stemming the growth of pediatric gliomas through histone modification.
    Neuro Oncol. 2021 Jan 20. pii: 6104497. doi: 10.1093.
    PubMed    


  379. DMYTRIW AA, Huang RY
    In search of predictive and response markers in antiangiogenic therapy of glioblastoma.
    Neuro Oncol. 2021 Jan 20. pii: 6104491. doi: 10.1093.
    PubMed    


  380. DANKNER M, Caron M, Al-Saadi T, Yu W, et al
    Invasive growth associated with Cold-Inducible RNA-Binding Protein expression drives recurrence of surgically resected brain metastases.
    Neuro Oncol. 2021 Jan 12. pii: 6089125. doi: 10.1093.
    PubMed     Abstract available


  381. WU S, Li X, Gao F, de Groot JF, et al
    PARP mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
    Neuro Oncol. 2021 Jan 12. pii: 6089123. doi: 10.1093.
    PubMed     Abstract available


  382. BENITEZ JA, Finlay D, Castanza A, Parisian AD, et al
    Pten Deficiency Leads To Proteasome Addiction, A Novel Vulnerability In Glioblastoma.
    Neuro Oncol. 2021 Jan 11. pii: 6081306. doi: 10.1093.
    PubMed     Abstract available


  383. GUTMAN DC, Young RJ
    IDH glioma radiogenomics in the era of deep learning.
    Neuro Oncol. 2021 Jan 8. pii: 6068851. doi: 10.1093.
    PubMed    


  384. SNUDERL M
    Molecular classification and deconvolution of the immune microenvironment in glioblastoma.
    Neuro Oncol. 2021 Jan 4. pii: 6062458. doi: 10.1093.
    PubMed    


  385. SHOFUDA T, Kanemura Y
    HDACs and MYC in medulloblastoma: how do HDAC inhibitors control MYC-amplified tumors?
    Neuro Oncol. 2021 Jan 4. pii: 6062389. doi: 10.1093.
    PubMed    


    December 2020
  386. SHAHZAD U, Taccone MS, Kumar SA, Okura H, et al
    Modeling human brain tumours in flies, worms, and zebrafish: From proof of principle to novel therapeutic targets.
    Neuro Oncol. 2020 Dec 30. pii: 6055605. doi: 10.1093.
    PubMed     Abstract available


  387. DUFOUR C, Foulon S, Geoffray A, Masliah-Planchon J, et al
    Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase 2 trial PNET HR+5.
    Neuro Oncol. 2020 Dec 30. pii: 6055191. doi: 10.1093.
    PubMed     Abstract available


  388. CHUNTOVA P, Chow F, Watchmaker P, Galvez M, et al
    Unique challenges for glioblastoma immunotherapy - Discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology.
    Neuro Oncol. 2020 Dec 24. pii: 6047273. doi: 10.1093.
    PubMed     Abstract available


  389. BEHLING F, Fodi C, Gepfner-Tuma I, Kaltenbach K, et al
    H3K27me3 loss indicates an increased risk of recurrence in the Tubingen meningioma cohort.
    Neuro Oncol. 2020 Dec 24. pii: 6046432. doi: 10.1093.
    PubMed     Abstract available


  390. KUKSIS M, Gao Y, Tran W, Hoey C, et al
    The Incidence of Brain Metastases Among Patients with Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
    Neuro Oncol. 2020 Dec 23. pii: 6046194. doi: 10.1093.
    PubMed     Abstract available


  391. CARLSON JC, Cantu-Gutierrez M, Lozzi B, Huang-Hobbs E, et al
    Identification of diverse tumor endothelial cell populations in malignant glioma.
    Neuro Oncol. 2020 Dec 23. pii: 6046199. doi: 10.1093.
    PubMed     Abstract available


  392. PATIL N, Kelly ME, Yeboa DN, Buerki RA, et al
    Epidemiology of Brainstem High-Grade Gliomas in Children and Adolescents in the United States, 2000-2017.
    Neuro Oncol. 2020 Dec 21. pii: 6042829. doi: 10.1093.
    PubMed     Abstract available


  393. PERWEIN T, Benesch M, Kandels D, Pietsch T, et al
    High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): Management strategies and results from the German LGG study group.
    Neuro Oncol. 2020 Dec 21. pii: 6042812. doi: 10.1093.
    PubMed     Abstract available


  394. BERNHARDT D, Combs SE
    Reply to: "Call of duty: neuro-oncology outpatient management during the COVID-19 pandemic in Milan, Italy".
    Neuro Oncol. 2020;22:1893.
    PubMed    


  395. YANG Z, Zhang Y, Li R, Yisikandaer A, et al
    Whole Brain Radiotherapy With and Without Concurrent Erlotinib in NSCLC with Brain Metastases: a multicentre, open-label, randomized, controlled phase 3 Trial.
    Neuro Oncol. 2020 Dec 17. pii: 6040795. doi: 10.1093.
    PubMed     Abstract available


  396. LIU Y, Li Z, Zhang M, Zhou H, et al
    Rolling-translated EGFR Variants Sustain EGFR Signaling and Promote Glioblastoma Tumorigenicity.
    Neuro Oncol. 2020 Dec 16. pii: 6039055. doi: 10.1093.
    PubMed     Abstract available


  397. HAYDAR D, Houke H, Chiang J, Yi Z, et al
    Cell surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.
    Neuro Oncol. 2020 Dec 15. pii: 6035165. doi: 10.1093.
    PubMed     Abstract available


  398. XIE R, Kessler T, Grosch J, Hai L, et al
    Tumor cell network integration in glioma represents a stemness feature.
    Neuro Oncol. 2020 Dec 15. pii: 6035154. doi: 10.1093.
    PubMed     Abstract available


  399. PUDUVALLI VK
    Demystifying Demethylator Sensitivity in Gliomas: Role for TERT and DNMT1.
    Neuro Oncol. 2020 Dec 2. pii: 6017324. doi: 10.1093.
    PubMed    


  400. HUANG J, Mehta M
    Can proton therapy reduce radiation-related lymphopenia in glioblastoma?
    Neuro Oncol. 2020 Dec 2. pii: 6017294. doi: 10.1093.
    PubMed    


  401. GENOVESI LA, Puttick S, Millar A, Kojic M, et al
    Patient derived orthotopic xenograft models of Medulloblastoma lack a functional blood brain barrier.
    Neuro Oncol. 2020 Dec 1. pii: 6015057. doi: 10.1093.
    PubMed     Abstract available


  402. YUAN M, White D, Resar L, Bar E, et al
    Conditional reprograming culture conditions facilitate growth of lower grade glioma models.
    Neuro Oncol. 2020 Dec 1. pii: 6015051. doi: 10.1093.
    PubMed     Abstract available


    November 2020
  403. KHASRAW M, Walsh KM, Heimberger AB, Ashley DM, et al
    What is the Burden of Proof for Tumor Mutational Burden in gliomas?
    Neuro Oncol. 2020 Nov 30. pii: 6012765. doi: 10.1093.
    PubMed     Abstract available


  404. LARA-VELAZQUEZ M, Zarco N, Carrano A, Phillipps J, et al
    Alpha 1-antichymotrypsin contributes to stem cell characteristics and enhances tumorigenicity of Glioblastoma.
    Neuro Oncol. 2020 Nov 29. pii: 6010432. doi: 10.1093.
    PubMed     Abstract available


  405. ZHENG ZQ, Chen JT, Zheng MC, Yang LJ, et al
    Nestin +/CD31 + Cells in the Hypoxic Perivascular Niche Regulate Glioblastoma Chemoresistance by Upregulating JAG1 and DLL4.
    Neuro Oncol. 2020 Nov 29. pii: 6010441. doi: 10.1093.
    PubMed     Abstract available


  406. NIU X, Yang Y, Zhou X, Zhang H, et al
    A prognostic nomogram for patients with newly diagnosed adult thalamic glioma in a surgical cohort.
    Neuro Oncol. 2020 Nov 27. pii: 6007003. doi: 10.1093.
    PubMed    


  407. KAUFMANN TJ, Smits M, Boxerman J, Huang R, et al
    Response to Letter to Editor.
    Neuro Oncol. 2020;22:1706-1707.
    PubMed    


  408. LE RHUN E, Weller M, Le Deley MC
    DEPOSEIN-how meaningful was the benefit from intrathecal chemotherapy?
    Neuro Oncol. 2020;22:1710-1711.
    PubMed    


  409. VOGELBAUM MA, Krivosheya D, Borghei-Razavi H, Sanai N, et al
    Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review.
    Neuro Oncol. 2020;22:1568-1579.
    PubMed     Abstract available


  410. OERMANN EK, Germano IM
    In the pursuit of glioma diagnosis - the challenges and opportunities of deep neural network augmented analyses.
    Neuro Oncol. 2020 Nov 12. pii: 5979500. doi: 10.1093.
    PubMed    


  411. ALBERT TK, Interlandi M, Sill M, Graf M, et al
    An extracellular vesicle-related gene expression signature identifies high-risk patients in medulloblastoma.
    Neuro Oncol. 2020 Nov 11. pii: 5974128. doi: 10.1093.
    PubMed     Abstract available


  412. MITCHELL K, Troike K, Silver DJ, Lathia JD, et al
    The evolution of the cancer stem cell state in glioblastoma - emerging insights into the next-generation of functional interactions.
    Neuro Oncol. 2020 Nov 11. pii: 5973946. doi: 10.1093.
    PubMed     Abstract available


  413. BERZERO G, Di Stefano AL, Ronchi S, Bielle F, et al
    IDH-wildtype lower grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification.
    Neuro Oncol. 2020 Nov 11. pii: 5973947. doi: 10.1093.
    PubMed     Abstract available


  414. GRAMATZKI D, Felsberg J, Roth P, Kaulich K, et al
    The molecular evolution of glioblastoma treated by gross total resection alone.
    Neuro Oncol. 2020 Nov 11. pii: 5973944. doi: 10.1093.
    PubMed    


  415. SAHEBJAM S, Forsyth PA, Tran ND, Arrington JA, et al
    Hypofractionated Stereotactic Re-Irradiation with Pembrolizumab and Bevacizumab in Patients with Recurrent High Grade Gliomas: Results from a Phase 1 Study.
    Neuro Oncol. 2020 Nov 11. pii: 5973945. doi: 10.1093.
    PubMed     Abstract available


  416. YI K, Zhan Q, Wang Q, Tan Y, et al
    PTRF/Cavin1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2.
    Neuro Oncol. 2020 Nov 3. pii: 5952479. doi: 10.1093.
    PubMed     Abstract available


  417. VITANZA NA, Biery MC, Myers C, Ferguson E, et al
    Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naive diffuse midline glioma models.
    Neuro Oncol. 2020 Nov 1. pii: 5948533. doi: 10.1093.
    PubMed     Abstract available


  418. MANJUNATH M, Yan J, Youn Y, Drucker KL, et al
    Functional analysis of low-grade glioma genetic variants predicts key target genes and transcription factors.
    Neuro Oncol. 2020 Nov 1. pii: 5948532. doi: 10.1093.
    PubMed     Abstract available


  419. DEJAEGHER J, Solie L, Hunin Z, Sciot R, et al
    DNA Methylation based glioblastoma subclassification is related to tumoral T cell infiltration and patient survival.
    Neuro Oncol. 2020 Nov 1. pii: 5948531. doi: 10.1093.
    PubMed     Abstract available


  420. KLEIN M, Drijver AJ, van den Bent MJ, Bromberg JC, et al
    Memory in low-grade glioma patients treated with radiotherapy or Temozolomide. A correlative analysis of EORTC study 22033-26033.
    Neuro Oncol. 2020 Nov 1. pii: 5948535. doi: 10.1093.
    PubMed     Abstract available


  421. SIEVERS P, Sill M, Schrimpf D, Stichel D, et al
    A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR.
    Neuro Oncol. 2020 Nov 1. pii: 5948536. doi: 10.1093.
    PubMed     Abstract available


  422. JI SY, Lee J, Lee JH, Lee ST, et al
    Radiological assessment schedule for high-grade glioma patients during the surveillance period using parametric modeling.
    Neuro Oncol. 2020 Nov 1. pii: 5948534. doi: 10.1093.
    PubMed     Abstract available


    October 2020
  423. OSTROM QT, Patil N, Cioffi G, Waite K, et al
    CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017.
    Neuro Oncol. 2020;22.
    PubMed     Abstract available


  424. TENG J, Hejazi S, Hiddingh L, Carvalho L, et al
    Corrigendum to: Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
    Neuro Oncol. 2020 Oct 28. pii: 5942594. doi: 10.1093.
    PubMed    


  425. CICONE F, Carideo L, Scaringi C, Romano A, et al
    Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET.
    Neuro Oncol. 2020 Oct 23. pii: 5936979. doi: 10.1093.
    PubMed     Abstract available


  426. MYNAREK M, Rutkowski S
    Young children with medulloblastoma: Important open questions and the high-risk dilemma.
    Neuro Oncol. 2020 Oct 23. pii: 5936023. doi: 10.1093.
    PubMed    


  427. GONDI V, Mehta MP
    Radiotherapy Innovations to Optimize Brain Metastases Control.
    Neuro Oncol. 2020 Oct 22. pii: 5934824. doi: 10.1093.
    PubMed    


  428. BROSSIER NM, Thondapu S, Cobb OM, Dahiya S, et al
    Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine Neurofibromatosis-1 optic glioma.
    Neuro Oncol. 2020 Oct 20. pii: 5932401. doi: 10.1093.
    PubMed     Abstract available


  429. CHO SJ, Sunwoo L, Baik SH, Bae YJ, et al
    Brain Metastasis Detection using Machine Learning: A Systematic Review and Meta-analysis.
    Neuro Oncol. 2020 Oct 19. pii: 5930826. doi: 10.1093.
    PubMed     Abstract available


  430. GROSSMAN SA
    The Duration of Adjuvant Temozolomide in Patients with Glioblastoma and the Law of Diminishing Returns.
    Neuro Oncol. 2020 Oct 19. pii: 5930402. doi: 10.1093.
    PubMed    


  431. SKINNER KR, Nabors LB, Miller CR
    Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics.
    Neuro Oncol. 2020 Oct 19. pii: 5930390. doi: 10.1093.
    PubMed    


  432. ZHUANG H, Wang Y, Cheng C, Shi S, et al
    The efficacy of anlotinib instead of glucocorticoids for edema induced by brain metastases in NSCLC patients with anti-PD1/PDL-1 immunotherapy.
    Neuro Oncol. 2020 Oct 19. pii: 5930379. doi: 10.1093.
    PubMed    


  433. YOUNGBLOOD MW, Miyagishima DF, Jin L, Gupte T, et al
    Associations of Meningioma Molecular Subgroup and Tumor Recurrence.
    Neuro Oncol. 2020 Oct 17. pii: 5928913. doi: 10.1093.
    PubMed     Abstract available


  434. LAMBA N, Kearney RB, Catalano PJ, Hassett MJ, et al
    Population-based estimates of survival among elderly patients with brain metastases.
    Neuro Oncol. 2020 Oct 17. pii: 5929216. doi: 10.1093.
    PubMed     Abstract available


  435. BEIG N, Singh S, Bera K, Prasanna P, et al
    Sexually dimorphic radiogenomic models identify distinct imaging and biological pathways that are prognostic of overall survival in Glioblastoma.
    Neuro Oncol. 2020 Oct 17. pii: 5929182. doi: 10.1093.
    PubMed     Abstract available


  436. BINDRA RS
    Penetrating the Brain Tumor Space with DNA Damage Response Inhibitors.
    Neuro Oncol. 2020 Oct 16. pii: 5924496. doi: 10.1093.
    PubMed    


  437. OPITZ CA, Turcan S
    From anti-aging drugs to cancer therapy: Is there a potential for sirtuin activators in gliomas?
    Neuro Oncol. 2020 Oct 16. pii: 5924499. doi: 10.1093.
    PubMed    


  438. ALNAHHAS I, Rayi A, Ong S, Giglio P, et al
    Management of gliomas in patients with Lynch Syndrome.
    Neuro Oncol. 2020 Oct 16. pii: 5924485. doi: 10.1093.
    PubMed    


  439. CHAMBERLAIN MC
    Leptomeningeal metastases: how best to assess response.
    Neuro Oncol. 2020;22:1417-1418.
    PubMed    


  440. ROSSI M, Gay L, Ambrogi F, Nibali MC, et al
    Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas.
    Neuro Oncol. 2020 Oct 13. pii: 5922564. doi: 10.1093.
    PubMed     Abstract available


    September 2020
  441. DAS S
    The ethics of neuro-oncology in the era of COVID-19: lessons to be learned.
    Neuro Oncol. 2020;22:1399.
    PubMed    


  442. XU W, Hu X, Zhang J
    Letter regarding article "Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion".
    Neuro Oncol. 2020;22:1400-1401.
    PubMed    


  443. KOTECHA R, Yomo S, Suh JH
    Response to letter regarding "Stereotactic radiosurgery for nonfunctioning pituitary adenomas: meta-analysis and International Society of Stereotactic Radiosurgery (ISRS) practice opinion".
    Neuro Oncol. 2020;22:1402-1403.
    PubMed    


  444. SHIREMAN JM, Ahmed AU
    Separate and not Equal: Sex Differences in JAM-A Tumor Suppression in Glioblastoma.
    Neuro Oncol. 2020 Sep 22. pii: 5909858. doi: 10.1093.
    PubMed    


  445. TSANG DS, Kim L, Liu ZA, Janzen L, et al
    Intellectual changes after radiation for children with brain tumors: which brain structures are most important?
    Neuro Oncol. 2020 Sep 16. pii: 5906521. doi: 10.1093.
    PubMed     Abstract available


  446. MILLER JJ, Cahill DP
    MGMT promoter methylation and hypermutant recurrence in IDH mutant lower-grade glioma.
    Neuro Oncol. 2020 Sep 14. pii: 5905585. doi: 10.1093.
    PubMed    


  447. WEI Y, Lu C, Zhou P, Zhao L, et al
    EIF4A3-induced circular RNA ASAP1(circASAP1) promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1/2 signaling.
    Neuro Oncol. 2020 Sep 14. pii: 5905565. doi: 10.1093.
    PubMed     Abstract available


  448. KHUONG-QUANG DA, Hansford JR
    Preoperative chemotherapy in medulloblastoma: A change in treatment paradigm?
    Neuro Oncol. 2020 Sep 12. pii: 5904992. doi: 10.1093.
    PubMed    


  449. JOHNSON RM, Phillips HS, Bais C, Brennan CW, et al
    Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma.
    Neuro Oncol. 2020 Sep 8. pii: 5902781. doi: 10.1093.
    PubMed     Abstract available


  450. BALANA C, Carrato C, Vaz MA
    Reply to: 'Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?'
    Neuro Oncol. 2020 Sep 4. pii: 5901531. doi: 10.1093.
    PubMed    


  451. PARK JW, Sahm F, Steffl B, Arrillaga-Romany I, et al
    TERT and DNMT1 expression predict sensitivity to decitabine in gliomas.
    Neuro Oncol. 2020 Sep 3. pii: 5901083. doi: 10.1093.
    PubMed     Abstract available


  452. KOTECHA R, Hall MD
    Impact of Radiotherapy Dosimetric Parameters on Neurocognitive Function in Brain Tumor Patients.
    Neuro Oncol. 2020 Sep 2. pii: 5900405. doi: 10.1093.
    PubMed    


    August 2020
  453. GUERREIRO STUCKLIN AS, Mueller S
    Opportunities for the treatment of NF1-associated low-grade gliomas: how to decide on the best treatment options for patients?
    Neuro Oncol. 2020 Aug 25. pii: 5896906. doi: 10.1093.
    PubMed    


  454. HE Y, Li J, Koga T, Ma J, et al
    Epidermal Growth Factor Receptor (EGFR) as a molecular determinant of glioblastoma response to dopamine receptor 2 (DRD2) inhibitors.
    Neuro Oncol. 2020 Aug 24. pii: 5896390. doi: 10.1093.
    PubMed     Abstract available


  455. ECKER J, Thatikonda V, Sigismondo G, Selt F, et al
    Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.
    Neuro Oncol. 2020 Aug 21. pii: 5895493. doi: 10.1093.
    PubMed     Abstract available


  456. NIE E, Jin X, Miao F, Yu T, et al
    TGF-beta1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT.
    Neuro Oncol. 2020 Aug 19. pii: 5894410. doi: 10.1093.
    PubMed     Abstract available


  457. ROSSMEISL JH, Herpai D, Quigley M, Cecere TE, et al
    Phase I trial of convection-enhanced delivery of IL13RA2 and EPHA2 receptor targeted cytotoxins in dogs with spontaneous intracranial gliomas.
    Neuro Oncol. 2020 Aug 19. pii: 5894210. doi: 10.1093.
    PubMed     Abstract available


  458. BOHM AK, DePetro J, Binding CE, Gerber A, et al
    In vitro modeling of glioblastoma initiation using PDGF-AA and p53-null neural progenitors.
    Neuro Oncol. 2020;22:1150-1161.
    PubMed     Abstract available


  459. SHI C, Ye Z, Han J, Ye X, et al
    BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma.
    Neuro Oncol. 2020;22:1114-1125.
    PubMed     Abstract available


  460. WICK A, Kessler T, Platten M, Meisner C, et al
    Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma.
    Neuro Oncol. 2020;22:1162-1172.
    PubMed     Abstract available


  461. YANG WC, Chen YF, Yang CC, Wu PF, et al
    Hippocampal Avoidance Whole-brain Radiotherapy without Memantine in Preserving Neurocognitive Function for Brain Metastases: A Phase II Blinded Randomized Trial.
    Neuro Oncol. 2020 Aug 13. pii: 5892223. doi: 10.1093.
    PubMed     Abstract available


  462. JOO L, Park JE, Park SY, Nam SJ, et al
    Extensive Peritumoral Edema and Brain-to-Tumor Interface MR Imaging Features Enable Prediction of Brain Invasion in Meningioma: Development and Validation.
    Neuro Oncol. 2020 Aug 13. pii: 5892102. doi: 10.1093.
    PubMed     Abstract available


  463. DANIEL AGS, Park KY, Roland JL, Dierker D, et al
    Functional connectivity within glioblastoma impacts overall survival.
    Neuro Oncol. 2020 Aug 13. pii: 5892093. doi: 10.1093.
    PubMed     Abstract available


  464. TRAN AN, Horbinski C
    Mesenchymal stem-like cells in glioblastoma.
    Neuro Oncol. 2020 Aug 12. pii: 5891766. doi: 10.1093.
    PubMed    


  465. MILANO MT, Chiang VLS, Soltys SG, Wang TJC, et al
    Executive Summary from American Radium Society's Appropriate Use Criteria on Neurocognition after stereotactic radiosurgery for multiple brain metastases.
    Neuro Oncol. 2020 Aug 11. pii: 5891284. doi: 10.1093.
    PubMed     Abstract available


  466. GUPTA T, Chatterjee A, Patil V
    Extended adjuvant temozolomide in newly-diagnosed glioblastoma: is more less?
    Neuro Oncol. 2020 Aug 10. pii: 5890517. doi: 10.1093.
    PubMed    


  467. PACKER RJ, MacDonald TJ
    Integrated Analysis of Pediatric Low-Grade Glioma (PLGGs): Clinical Implications and the Path Forward.
    Neuro Oncol. 2020 Aug 8. pii: 5885400. doi: 10.1093.
    PubMed    


  468. FULTS DW
    Marauding Monocytes, Macrophages, and Microglia in Gliomas.
    Neuro Oncol. 2020 Aug 8. pii: 5885299. doi: 10.1093.
    PubMed    


  469. HOSSAIN JA, Miletic H
    Letter regarding "Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas".
    Neuro Oncol. 2020 Aug 8. pii: 5885399. doi: 10.1093.
    PubMed    


  470. MOHAN R, Liu AY, Brown PD, Mahajan A, et al
    Proton Therapy Reduces the Likelihood of High-Grade Radiation-Induced Lymphopenia in Glioblastoma Patients: Phase II Randomized Study of Protons vs. Photons.
    Neuro Oncol. 2020 Aug 5. pii: 5880625. doi: 10.1093.
    PubMed     Abstract available


    July 2020
  471. ARANA E, Arribas LA
    Letter regarding "Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases".
    Neuro Oncol. 2020 Jul 31. pii: 5879447. doi: 10.1093.
    PubMed    


  472. CHOI YS, Bae S, Chang JH, Kang SG, et al
    Fully Automated Hybrid Approach to Predict the IDH Mutation Status of Gliomas via Deep Learning and Radiomics.
    Neuro Oncol. 2020 Jul 24. pii: 5876011. doi: 10.1093.
    PubMed     Abstract available


  473. WILCOX JA, Boire AA
    Palliation for all people: alleviating racial disparities in supportive care for brain metastases.
    Neuro Oncol. 2020 Jul 21. pii: 5874496. doi: 10.1093.
    PubMed    


  474. LAMBA N, Catalano PJ, Haas-Kogan DA, Wen PY, et al
    Utility of claims data for delineation of intracranial treatment among patients with brain metastases.
    Neuro Oncol. 2020 Jul 21. pii: 5874115. doi: 10.1093.
    PubMed    


  475. WORONIECKA K, Fecci PE
    Immuno-Synergy? Neoantigen Vaccines and Checkpoint Blockade in Glioblastoma.
    Neuro Oncol. 2020 Jul 21. pii: 5874112. doi: 10.1093.
    PubMed    


  476. CHILUKURI S, Jalali R
    Reassuring quality of life in younger childhood (<4 years) brain tumor survivors treated with proton beam therapy.
    Neuro Oncol. 2020 Jul 17. pii: 5873257. doi: 10.1093.
    PubMed    


  477. SCHMAINDA KM, Prah MA, Marques H, Kim E, et al
    Value of Dynamic Contrast Perfusion MRI to Predict Early Response to Bevacizumab in Newly Diagnosed Glioblastoma: Results from ACRIN 6686 Multi-Center Trial.
    Neuro Oncol. 2020 Jul 17. pii: 5873138. doi: 10.1093.
    PubMed     Abstract available


  478. HOLLON TC, Pandian B, Urias E, Save AV, et al
    Rapid, label-free detection of diffuse glioma recurrence using intraoperative stimulated Raman histology and deep neural networks.
    Neuro Oncol. 2020 Jul 16. pii: 5872473. doi: 10.1093.
    PubMed     Abstract available


  479. JIN L, Shi F, Chun Q, Chen H, et al
    Artificial Intelligence Neuropathologist for Glioma Classification using Deep Learning on Hematoxylin and Eosin Stained Slide images and Molecular Markers.
    Neuro Oncol. 2020 Jul 14. pii: 5871429. doi: 10.1093.
    PubMed     Abstract available


  480. SANTANGELO A, Rossato M, Lombardi G, Benfatto S, et al
    A Molecular Signature associated with prolonged survival in Glioblastoma patients treated with Regorafenib.
    Neuro Oncol. 2020 Jul 14. pii: 5871069. doi: 10.1093.
    PubMed     Abstract available


  481. ALMAHARIQ MF, Quinn TJ, Arden JD, Roskos PT, et al
    Pulsed Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma.
    Neuro Oncol. 2020 Jul 13. pii: 5870764. doi: 10.1093.
    PubMed     Abstract available


  482. BAKAS S, Ormond DR, Alfaro KD, Smits M, et al
    iGLASS: Imaging integration into the Glioma Longitudinal AnalySiS Consortium.
    Neuro Oncol. 2020 Jul 9. pii: 5869362. doi: 10.1093.
    PubMed    


  483. KARREMAN MA, Winkler F
    Targeting an adhesion molecule to prevent brain colonization of lung cancer.
    Neuro Oncol. 2020;22:899-900.
    PubMed    


  484. GEURTS M, van den Bent MJ
    Fast-growing oligodendrogliomas are aggressive tumors-the real life biomarker?
    Neuro Oncol. 2020;22:907-908.
    PubMed    


  485. COLO F, Larrouquere L, Rivoirard R, Loiseau H, et al
    Bevacizumab in progressive disseminated atypical choroid plexus papilloma in adults.
    Neuro Oncol. 2020;22:1046-1047.
    PubMed    


  486. JAIN R, Johnson DR, Patel SH, Castillo M, et al
    "Real world" use of a highly reliable imaging sign: "T2-FLAIR mismatch" for identification of IDH mutant astrocytomas.
    Neuro Oncol. 2020;22:936-943.
    PubMed     Abstract available


  487. ROUX A, Tauziede-Espariat A, Zanello M, Peeters S, et al
    Imaging growth as a predictor of grade of malignancy and aggressiveness of IDH-mutant and 1p/19q-codeleted oligodendrogliomas in adults.
    Neuro Oncol. 2020;22:993-1005.
    PubMed     Abstract available


  488. AZIZI AA, Walker DA, Liu JF, Sehested A, et al
    NF1 optic pathway glioma. Analysing risk factors for visual outcome and indications to treat.
    Neuro Oncol. 2020 Jul 6. pii: 5867970. doi: 10.1093.
    PubMed     Abstract available


  489. VENKATARAMANI V, Tanev DI, Kuner T, Wick W, et al
    Synaptic Input to Brain Tumors: Clinical Implications.
    Neuro Oncol. 2020 Jul 5. pii: 5867510. doi: 10.1093.
    PubMed     Abstract available


  490. CARAI A, Locatelli F, Mastronuzzi A
    Delayed referral of pediatric brain tumors during COVID-19 pandemic.
    Neuro Oncol. 2020 Jul 5. pii: 5867513. doi: 10.1093.
    PubMed    


  491. DUNN GP, Cloughesy TF, Maus MV, Prins RM, et al
    Emerging Immunotherapies for Malignant Glioma: From Immunogenomics to Cell Therapy.
    Neuro Oncol. 2020 Jul 2. pii: 5866670. doi: 10.1093.
    PubMed     Abstract available


  492. VAN DEN BENT M, Eoli M, Sepulveda JM, Smits M, et al
    INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
    Neuro Oncol. 2020 Jul 1. pii: 5866079. doi: 10.1093.
    PubMed    


    June 2020
  493. ZHANG A, Tao W, Zhai K, Fang X, et al
    Protein Sumoylation with SUMO1 Promoted by Pin1 in Glioma Stem Cells Augments Glioblastoma Malignancy.
    Neuro Oncol. 2020 Jun 27. pii: 5864095. doi: 10.1093.
    PubMed     Abstract available


  494. TURAGA SM, Silver DJ, Bayik D, Paouri E, et al
    JAM-A functions as a female microglial tumor suppressor in glioblastoma.
    Neuro Oncol. 2020 Jun 27. pii: 5864028. doi: 10.1093.
    PubMed     Abstract available


  495. VAN TELLINGEN O, de Gooijer MC, Sarkaria JN, Elmquist WF, et al
    Comments on: "Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity".
    Neuro Oncol. 2020 Jun 18. pii: 5859434. doi: 10.1093.
    PubMed    


  496. BOXERMAN JL, Quarles CC, Hu LS, Erickson BJ, et al
    Consensus Recommendations for a Dynamic Susceptibility Contrast MRI Protocol for Use in High-Grade Gliomas.
    Neuro Oncol. 2020 Jun 9. pii: 5855183. doi: 10.1093.
    PubMed     Abstract available


  497. EATON BR, Yock TI
    Radiation for Pediatric Low Grade Gliomas: who will benefit and how late is soon enough?
    Neuro Oncol. 2020 Jun 9. pii: 5855151. doi: 10.1093.
    PubMed    


  498. JARAIZ-RODRIGUEZ M, Talaveron R, Garcia-Vicente L, Pelaz SG, et al
    Erratum to 'Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo'.
    Neuro Oncol. 2020 Jun 9. pii: 5854970. doi: 10.1093.
    PubMed    


  499. BENNETT J, Bouffet E
    Neuro-oncology in adolescents and young adults-an unmet need.
    Neuro Oncol. 2020;22:752-753.
    PubMed    


  500. HU LS, Swanson KR
    Roadmap for the clinical integration of radiomics in neuro-oncology.
    Neuro Oncol. 2020;22:743-745.
    PubMed    


  501. GROSSMAN SA, Romo CG, Rudek MA, Supko J, et al
    Baseline Requirements for Novel Agents Being Considered for Phase II/III Brain Cancer Efficacy Trials:Conclusions from the Adult Brain Tumor Consortium's First Workshop on CNS Drug Delivery.
    Neuro Oncol. 2020 Jun 7. pii: 5854364. doi: 10.1093.
    PubMed    


  502. LEACH JL, Roebker J, Schafer A, Baugh J, et al
    MR Imaging features of Diffuse Intrinsic Pontine Glioma (DIPG) and Relationship to Overall Survival: Report from the International DIPG Registry.
    Neuro Oncol. 2020 Jun 6. pii: 5854320. doi: 10.1093.
    PubMed     Abstract available


  503. ZHANG LH, Yin YH, Chen HZ, Feng SY, et al
    TRIM24 Promotes Stemness and Invasiveness of Glioblastoma Cells via Activating SOX2 Expression.
    Neuro Oncol. 2020 Jun 3. pii: 5850997. doi: 10.1093.
    PubMed     Abstract available


  504. KOTECHA R, Mehta MP
    Extreme Hypofractionation for Newly Diagnosed Glioblastoma: Rationale, Dose, Techniques, and Outcomes.
    Neuro Oncol. 2020 Jun 1. pii: 5849843. doi: 10.1093.
    PubMed    


  505. MASSIMINO M, Giangaspero F
    Editorial: High-grade gliomas in adolescents and young adults reveal histomolecular differences vis-a-vis their adult and pediatric counterparts.
    Neuro Oncol. 2020 Jun 1. pii: 5849851. doi: 10.1093.
    PubMed    


  506. HAGGIAGI A, Lassman AB
    Newly diagnosed glioblastoma in the elderly: when is temozolomide alone enough?
    Neuro Oncol. 2020 Jun 1. pii: 5849858. doi: 10.1093.
    PubMed    


  507. SAMMONS S, Van Swearingen AED, Anders CK
    Receptor Discordance in Breast Cancer Brain Metastases: When Knowledge is Power.
    Neuro Oncol. 2020 Jun 1. pii: 5849911. doi: 10.1093.
    PubMed    


    May 2020
  508. BUCCARELLI M, Lulli V, Giuliani A, Signore M, et al
    Deregulated expression of the imprinted DLK1-DIO3 region in Glioblastoma Stem-like Cells: tumor suppressor role of lncRNA MEG3.
    Neuro Oncol. 2020 May 27. pii: 5847771. doi: 10.1093.
    PubMed     Abstract available


  509. KAUR E, Nair J, Ghorai A, Mishra SV, et al
    Inhibition of SETMAR-H3K36me2-NHEJ repair axis in residual disease cells prevent glioblastoma recurrence.
    Neuro Oncol. 2020 May 27. pii: 5847629. doi: 10.1093.
    PubMed     Abstract available


  510. BARONI LV, Sampor C, Gonzalez A, Lubieniecki F, et al
    Bridging the treatment gap in infant medulloblastoma: Molecularly informed outcomes of a globally feasible regimen.
    Neuro Oncol. 2020 May 15. pii: 5837622. doi: 10.1093.
    PubMed     Abstract available


  511. DI STEFANO AL, Picca A, Saragoussi E, Bielle F, et al
    Clinical, molecular and radiomic profile of gliomas with FGFR3-TACC3 fusions.
    Neuro Oncol. 2020 May 15. pii: 5837595. doi: 10.1093.
    PubMed     Abstract available


  512. SANTANA-CODINA N, Gonzalez J, Sierra A
    Reply to Letter to the Editor.
    Neuro Oncol. 2020;22:734-735.
    PubMed    


  513. BRANDSMA D, van den Bent MJB
    Quantification of leptomeningeal metastases from solid tumors remains a challenging issue.
    Neuro Oncol. 2020;22:592-593.
    PubMed    


  514. LOBBOUS M, Nabors LB
    A troublesome burden, the amplification of EGFR in glioblastoma!
    Neuro Oncol. 2020;22:594-595.
    PubMed    


  515. SCHELL M, Pfluger I, Brugnara G, Isensee F, et al
    Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.
    Neuro Oncol. 2020 May 11. pii: 5836012. doi: 10.1093.
    PubMed     Abstract available


  516. GOLDMAN S, Pollack IF, Jakacki RI, Billups CA, et al
    Phase II study of peginterferon alpha-2b for patients with unresectable or recurrent craniopharyngiomas: a Pediatric Brain Tumor Consortium report.
    Neuro Oncol. 2020 May 11. pii: 5836011. doi: 10.1093.
    PubMed     Abstract available


  517. GRIL B, Wei D, Zimmer AS, Robinson C, et al
    A HER2 Antibody Drug Conjugate Controls Growth of Breast Cancer Brain Metastases in Hematogenous Xenograft Models, with Heterogeneous Blood-Tumor Barrier Penetration Unlinked to a Passive Marker.
    Neuro Oncol. 2020 May 9. pii: 5835334. doi: 10.1093.
    PubMed     Abstract available


  518. ECKEL-PASSOW JE, Drucker KL, Kollmeyer TM, Kosel ML, et al
    Adult Diffuse Glioma GWAS by Molecular Subtype Identifies Variants in D2HGDH and FAM20C.
    Neuro Oncol. 2020 May 9. pii: 5835318. doi: 10.1093.
    PubMed     Abstract available


  519. BERNHARDT D, Wick W, Weiss SE, Sahgal A, et al
    Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas.
    Neuro Oncol. 2020 May 5. pii: 5829911. doi: 10.1093.
    PubMed     Abstract available


    April 2020
  520. HANNA C, Kurian KM, Williams K, Watts C, et al
    Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.
    Neuro Oncol. 2020 Apr 29. pii: 5826799. doi: 10.1093.
    PubMed     Abstract available


  521. TABRIZI S, Trippa L, Cagney D, Tanguturi S, et al
    A Quantitative Framework for Modeling COVID-19 Risk During Adjuvant Therapy Using Published Randomized Trials of Glioblastoma in the Elderly.
    Neuro Oncol. 2020 Apr 27. pii: 5825707. doi: 10.1093.
    PubMed     Abstract available


  522. BALANA C, Vaz MA, Sepulveda JM, Mesia C, et al
    A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01).
    Neuro Oncol. 2020 Apr 24. pii: 5824410. doi: 10.1093.
    PubMed     Abstract available


  523. WEN PY, Weller M, Lee EQ, Alexander BA, et al
    Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions.
    Neuro Oncol. 2020 Apr 24. pii: 5824407. doi: 10.1093.
    PubMed     Abstract available


  524. HUANG RY, Young RJ, Ellingson BM, Veeraraghavan H, et al
    Volumetric Analysis of IDH-Mutant Lower-Grade Glioma: A Natural History Study of Tumor Growth Rates Before and After Treatment.
    Neuro Oncol. 2020 Apr 24. pii: 5824395. doi: 10.1093.
    PubMed     Abstract available


  525. YANG WB, Hsu CC, Hsu TI, Liou JP, et al
    Increased activation of HDAC1/2/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma.
    Neuro Oncol. 2020 Apr 24. pii: 5824394. doi: 10.1093.
    PubMed     Abstract available


  526. CLUCERU J, Nelson SJ, Wen Q, Phillips JJ, et al
    Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas.
    Neuro Oncol. 2020 Apr 22. pii: 5823723. doi: 10.1093.
    PubMed     Abstract available


  527. DHALL G, O'Neil SH, Ji L, Haley K, et al
    Excellent Outcome of Young Children with Nodular Desmoplastic Medulloblastoma Treated on "Head Start" III: A Multi-Institutional, Prospective Clinical Trial.
    Neuro Oncol. 2020 Apr 18. pii: 5821791. doi: 10.1093.
    PubMed     Abstract available


  528. BELLAT V, Alcaina Y, Tung CH, Ting R, et al
    A Combined Approach of Convection-Enhanced Delivery of Peptide Nanofiber Reservoir to Prolong Delivery of DM1 for Diffuse Intrinsic Pontine Glioma Treatment.
    Neuro Oncol. 2020 Apr 17. pii: 5821265. doi: 10.1093.
    PubMed     Abstract available


  529. KRIEGER TG, Tirier SM, Park J, Jechow K, et al
    Modeling glioblastoma invasion using human brain organoids and single-cell transcriptomics.
    Neuro Oncol. 2020 Apr 16. pii: 5820825. doi: 10.1093.
    PubMed     Abstract available


  530. KEUNEN O, Niclou SP
    A prominent role for MR spectroscopy in the clinical management of brain tumors?
    Neuro Oncol. 2020 Apr 15. pii: 5820221. doi: 10.1093.
    PubMed    


  531. MOHILE NA, Blakeley JO, Gatson NTN, Hottinger AF, et al
    Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 Pandemic.
    Neuro Oncol. 2020 Apr 11. pii: 5818980. doi: 10.1093.
    PubMed     Abstract available


  532. GUERRINI-ROUSSEAU L, Abbas R, Huybrechts S, Kieffer-Renaux V, et al
    Role of neoadjuvant chemotherapy in metastatic medulloblastoma: a comparative study in 92 children.
    Neuro Oncol. 2020 Apr 8. pii: 5817932. doi: 10.1093.
    PubMed     Abstract available


  533. FUKUOKA K, Mamatjan Y, Tatevossian R, Zapotocky M, et al
    Clinical impact of combined epigenetic and molecular analysis of pediatric low grade gliomas.
    Neuro Oncol. 2020 Apr 3. pii: 5815300. doi: 10.1093.
    PubMed     Abstract available


  534. TABRIZI S, Shih HA
    The Path Forward for Radiation Therapy in the Management of Low-Grade Gliomas.
    Neuro Oncol. 2020 Apr 2. pii: 5815323. doi: 10.1093.
    PubMed    


  535. ULLRICH NJ, Prabhu SP, Reddy AT, Fisher MJ, et al
    A Phase II Study of Continuous Oral mTOR Inhibitor Everolimus for Recurrent, Radiographic-Progressive Neurofibromatosis Type 1-Associated Pediatric Low-Grade Glioma: A Neurofibromatosis Clinical Trials Consortium Study.
    Neuro Oncol. 2020 Apr 1. pii: 5814308. doi: 10.1093.
    PubMed     Abstract available


  536. LEE S, Latha K, Manyam G, Yang Y, et al
    Role of CX3CR1 Signaling in Malignant Transformation of Gliomas.
    Neuro Oncol. 2020 Apr 1. pii: 5814292. doi: 10.1093.
    PubMed     Abstract available


    March 2020
  537. GODA JS, Dutta D, Krishna U, Goswami S, et al
    Hippocampal radiotherapy dose-constraints for predicting long-term neurocognitive outcomes: Mature data from a prospective trial in young patients with brain tumors.
    Neuro Oncol. 2020 Mar 30. pii: 5813654. doi: 10.1093.
    PubMed     Abstract available


  538. TAYLOR JT, Ellison S, Pandele A, Wood S, et al
    Actinomycin D Downregulates Sox2 and Improves Survival in Preclinical Models of Recurrent Glioblastoma.
    Neuro Oncol. 2020 Mar 30. pii: 5813520. doi: 10.1093.
    PubMed     Abstract available


  539. YOSHIDA GJ
    Comment on "GRP94 promotes brain metastasis by engaging pro-survival autophagy".
    Neuro Oncol. 2020 Mar 27. pii: 5812835. doi: 10.1093.
    PubMed    


  540. FEDERICI L, Capelle L, Annereau M, Bielle F, et al
    5-Azacitidine in Patients with IDH1/2-mutant Recurrent Glioma.
    Neuro Oncol. 2020 Mar 26. pii: 5812065. doi: 10.1093.
    PubMed    


  541. PENG J, Zhou H, Tang O, Chang K, et al
    Evaluation of RAPNO criteria in medulloblastoma and other leptomeningeal seeding tumors using MRI and clinical data.
    Neuro Oncol. 2020 Mar 26. pii: 5811685. doi: 10.1093.
    PubMed     Abstract available


  542. SONG J, Kadaba P, Kravitz A, Hormigo A, et al
    Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors.
    Neuro Oncol. 2020 Mar 20. pii: 5810282. doi: 10.1093.
    PubMed     Abstract available


  543. GILL CM, Loewenstern J, Rutland JW, Arib H, et al
    Recurrent IDH Mutations in High-Grade Meningioma.
    Neuro Oncol. 2020 Mar 17. pii: 5808805. doi: 10.1093.
    PubMed    


  544. BAILEY CP, Figueroa M, Gangadharan A, Yang Y, et al
    Pharmacologic inhibition of lysine specific demethylase-1 (LSD1) as a therapeutic and immune-sensitization strategy in pediatric high grade glioma (pHGG).
    Neuro Oncol. 2020 Mar 13. pii: 5804621. doi: 10.1093.
    PubMed     Abstract available


  545. MATHUR R, Zhang Y, Grimmer MR, Hong C, et al
    MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
    Neuro Oncol. 2020 Mar 13. pii: 5804625. doi: 10.1093.
    PubMed     Abstract available


  546. PUDUVALLI VK, Wu J, Yuan Y, Armstrong TS, et al
    A Bayesian Adaptive Randomized Phase II Multicenter Trial of Bevacizumab with or without Vorinostat in Adults with Recurrent Glioblastoma.
    Neuro Oncol. 2020 Mar 13. pii: 5804658. doi: 10.1093.
    PubMed     Abstract available


  547. GORELYSHEV A, Mazerkina N, Medvedeva O, Vasilyev E, et al
    Second-hit APC mutation in a familial adamantinomatous craniopharyngioma.
    Neuro Oncol. 2020 Mar 12. pii: 5805241. doi: 10.1093.
    PubMed    


  548. EBERHART C
    Astrocytes - New Stars In The Medulloblastoma Firmament.
    Neuro Oncol. 2020 Mar 11. pii: 5802783. doi: 10.1093.
    PubMed    


  549. KHATUA S, Cooper LJN, Sandberg DI, Ketonen L, et al
    Phase I study of intraventricular infusions of autologous ex-vivo-expanded NK cells in children with recurrent medulloblastoma and ependymoma.
    Neuro Oncol. 2020 Mar 10. pii: 5802287. doi: 10.1093.
    PubMed     Abstract available


  550. LAMBA N, Mehanna E, Kearney RB, Catalano PJ, et al
    Racial disparities in supportive medication use among older patients with brain metastases: A population-based analysis.
    Neuro Oncol. 2020 Mar 9. pii: 5800995. doi: 10.1093.
    PubMed     Abstract available


  551. LIU CJ, Schaettler M, Blaha DT, Bowman-Kirigin JA, et al
    Treatment of an Aggressive Orthotopic Murine Glioblastoma Model with Combination Checkpoint Blockade and a Multivalent Neoantigen Vaccine.
    Neuro Oncol. 2020 Mar 5. pii: 5781186. doi: 10.1093.
    PubMed     Abstract available


  552. SIDDAWAY R, Hawkins C
    Modeling DIPG in the mouse brainstem.
    Neuro Oncol. 2020;22:307-308.
    PubMed    


  553. KOTECHA R, Sahgal A, Rubens M, De Salles A, et al
    Stereotactic radiosurgery for non-functioning pituitary adenomas: meta-analysis and International Stereotactic Radiosurgery Society practice opinion.
    Neuro Oncol. 2020;22:318-332.
    PubMed     Abstract available


  554. LASOCKI A, Khoo C, Lau PKH, Kok DL, et al
    High-resolution MRI demonstrates that more than 90% of small intracranial melanoma metastases develop in close relationship to the leptomeninges.
    Neuro Oncol. 2020;22:423-432.
    PubMed     Abstract available


    February 2020
  555. STOECKLEIN VM, Stoecklein S, Galie F, Ren J, et al
    Resting-state fMRI Detects Alterations in Whole Brain Connectivity Related to Tumor Biology in Glioma Patients.
    Neuro Oncol. 2020 Feb 28. pii: 5764143. doi: 10.1093.
    PubMed     Abstract available


  556. JIANG H, Yang K, Ren X, Cui Y, et al
    Retraction notice: Diffuse midline glioma with H3 K27M mutation: a comparison integrating the clinical, radiological, and molecular features between adult and pediatric patients.
    Neuro Oncol. 2020 Feb 25. pii: 5756150. doi: 10.1093.
    PubMed    


  557. LIM M, Pant A
    Understanding innate immune response in Glioblastoma in search for a way forward.
    Neuro Oncol. 2020 Feb 22. pii: 5751793. doi: 10.1093.
    PubMed    


  558. HIMES BT, Peterson TE, de Mooij T, Garcia MLMC, et al
    The role of extracellular vesicles and PD-L1 in glioblastoma-mediated immunosuppressive monocyte induction.
    Neuro Oncol. 2020 Feb 21. pii: 5742588. doi: 10.1093.
    PubMed     Abstract available


  559. MENDEZ FM, Nunez FJ, Garcia-Fabiani MB, Haase S, et al
    Epigenetic reprogramming and chromatin accessibility in pediatric diffuse intrinsic pontine gliomas: a neural developmental disease.
    Neuro Oncol. 2020;22:195-206.
    PubMed     Abstract available


  560. BALASUBRAMANIYAN V, Bhat K
    Targeting pyrimidine metabolism for glioblastoma therapy.
    Neuro Oncol. 2020;22:169-170.
    PubMed    


  561. OSTROM QT, Kruchko C, Barnholtz-Sloan JS
    Pilocytic astrocytomas: where do they belong in cancer reporting?
    Neuro Oncol. 2020;22:298-300.
    PubMed    



  562. Corrigendum to Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.
    Neuro Oncol. 2020 Feb 18. pii: 5740122. doi: 10.1093.
    PubMed    


  563. EATON BR, Goldberg S, Tarbell NJ, Lawell MP, et al
    Long-term Health Related Quality of Life in Pediatric Brain Tumor Survivors Treated with Proton Radiotherapy at <4 Years of Age.
    Neuro Oncol. 2020 Feb 17. pii: 5737810. doi: 10.1093.
    PubMed     Abstract available


  564. MUNSTERBERG J, Loreth D, Brylka L, Werner S, et al
    ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium.
    Neuro Oncol. 2020 Feb 17. pii: 5737760. doi: 10.1093.
    PubMed     Abstract available


  565. PACKER RJ, Iavarone A, Jones DTW, Blakeley JO, et al
    Implications of New Understandings of Gliomas in Children and Adults with NF1: Report of a Consensus Conference.
    Neuro Oncol. 2020 Feb 14. pii: 5736008. doi: 10.1093.
    PubMed     Abstract available


  566. FRITAH S, Niclou SP
    Dual blockade of STAT3 and EGFR, a key to unlock drug resistance in Glioblastoma?
    Neuro Oncol. 2020 Feb 14. pii: 5736011. doi: 10.1093.
    PubMed    


  567. TIWARI V, Daoud EV, Hatanpaa KJ, Gao A, et al
    Glycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness.
    Neuro Oncol. 2020 Feb 14. pii: 5735772. doi: 10.1093.
    PubMed     Abstract available


  568. SASTRY NG, Wan X, Huang T, Alvarez AA, et al
    LY6K Promotes Glioblastoma Tumorigenicity via CAV-1-Mediated ERK1/2 Signaling Enhancement.
    Neuro Oncol. 2020 Feb 14. pii: 5735689. doi: 10.1093.
    PubMed     Abstract available


  569. ACHARYA S, Liu JF, Tatevossian RG, Chiang J, et al
    Risk stratification in pediatric low-grade glioma and glioneuronal tumor treated with radiation therapy: An integrated clinicopathologic and molecular analysis.
    Neuro Oncol. 2020 Feb 13. pii: 5734990. doi: 10.1093.
    PubMed     Abstract available


  570. KAUFMANN TJ, Smits M, Boxerman J, Huang R, et al
    Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases (BTIP-BM).
    Neuro Oncol. 2020 Feb 12. pii: 5734626. doi: 10.1093.
    PubMed     Abstract available


  571. ZINNHARDT B, Muther M, Roll W, Backhaus P, et al
    TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma.
    Neuro Oncol. 2020 Feb 12. pii: 5734268. doi: 10.1093.
    PubMed     Abstract available


  572. SPERDUTO PW, Mesko S, Li J, Cagney D, et al
    Estrogen, Progesterone and HER2 Receptor Discordance Between Primary Tumor and Brain Metastases in Breast Cancer and Its Effect on Treatment and Survival.
    Neuro Oncol. 2020 Feb 8. pii: 5731396. doi: 10.1093.
    PubMed     Abstract available


  573. DE VRIES F
    Letter regarding "Cognitive outcomes in meningioma patients undergoing surgery: individual changes over time and predictors of late cognitive functioning".
    Neuro Oncol. 2020 Feb 6. pii: 5728672. doi: 10.1093.
    PubMed    


  574. ROUX A, Pallud J, Saffroy R, Edjlali-Goujon M, et al
    High-grade gliomas in adolescents and young adults highlight histomolecular differences with their adult and paediatric counterparts.
    Neuro Oncol. 2020 Feb 6. pii: 5728472. doi: 10.1093.
    PubMed     Abstract available


  575. HAN MZ, Huang B, Ni SL, Wang J, et al
    A validated prognostic nomogram for patients with newly diagnosed lower-grade gliomas in a large-scale Asian cohort.
    Neuro Oncol. 2020 Feb 6. pii: 5728477. doi: 10.1093.
    PubMed    


  576. BAXTER PA, Su JM, Onar-Thomas A, Billups CA, et al
    A Phase I/II Study of Veliparib (ABT-888) with Radiation and Temozolomide in Newly Diagnosed Diffuse Pontine Glioma: A Pediatric Brain Tumor Consortium Study.
    Neuro Oncol. 2020 Feb 3. pii: 5721145. doi: 10.1093.
    PubMed     Abstract available


    January 2020
  577. AZOULAY M, Chang SD, Gibbs IC, Hancock SL, et al
    A Phase I/II Trial of 5-Fraction Stereotactic Radiosurgery with 5-mm Margins with Concurrent Temozolomide in Newly Diagnosed Glioblastoma: Primary Outcomes.
    Neuro Oncol. 2020 Jan 31. pii: 5718251. doi: 10.1093.
    PubMed     Abstract available


  578. RIJNEN SJM, De Baene W, Rutten GM, Gehring K, et al
    In reply to the letter to the editor regarding 'Cognitive outcomes in meningioma patients undergoing surgery: Individual changes over time and predictors of late cognitive functioning'.
    Neuro Oncol. 2020 Jan 30. pii: 5718243. doi: 10.1093.
    PubMed    


  579. BREEN WG, Anderson SK, Carrero XW, Brown PD, et al
    Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.
    Neuro Oncol. 2020 Jan 30. pii: 5718239. doi: 10.1093.
    PubMed     Abstract available


  580. LEE EQ, Weller M, Sul J, Bagley SJ, et al
    Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.
    Neuro Oncol. 2020 Jan 24. pii: 5715205. doi: 10.1093.
    PubMed     Abstract available


  581. HULSBERGEN AFC, Claes A, Kavouridis VK, Ansaripour A, et al
    Subtype switching in breast cancer brain metastases: a multicenter analysis.
    Neuro Oncol. 2020 Jan 23. pii: 5714300. doi: 10.1093.
    PubMed     Abstract available


  582. MUSKENS IS, de Smith AJ, Zhang C, Hansen HM, et al
    Germline cancer predisposition variants and pediatric glioma: a population-based study in California.
    Neuro Oncol. 2020 Jan 23. pii: 5714303. doi: 10.1093.
    PubMed     Abstract available


  583. RAO G, Sonabend A, Heimberger AB
    Are radiation and response biomarkers the missing elements for efficacious immunotherapy for glioma patients?
    Neuro Oncol. 2020 Jan 22. pii: 5714174. doi: 10.1093.
    PubMed    


  584. MOURAVIEV A, Detsky J, Sahgal A, Ruschin M, et al
    Use of Radiomics for the Prediction of Local Control of Brain Metastases After Stereotactic Radiosurgery.
    Neuro Oncol. 2020 Jan 20. pii: 5709657. doi: 10.1093.
    PubMed     Abstract available


  585. COMBA A, Dunn PJ, Argento AE, Kadiyala P, et al
    FYN tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates anti-glioma immune responses.
    Neuro Oncol. 2020 Jan 17. pii: 5707582. doi: 10.1093.
    PubMed     Abstract available


  586. CIMINO PJ
    Analogous survival for patients with glioblastoma diagnosed by either histopathological or molecular features.
    Neuro Oncol. 2020 Jan 17. pii: 5707595. doi: 10.1093.
    PubMed    


  587. POPOVSKI D, Huang A
    Targeting MEK/MELK in atypical teratoid rhabdoid tumor: a treatment approach aimed at exploiting blood-brain barrier deficiencies.
    Neuro Oncol. 2020;22:3-4.
    PubMed    


  588. TRIFILETTI DM, Brown PD
    Leptomeningeal disease following local brain irradiation: a new frontier.
    Neuro Oncol. 2020;22:5-6.
    PubMed    


  589. TEW BY, Legendre C, Schroeder MA, Triche T, et al
    Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones.
    Neuro Oncol. 2020;22:70-83.
    PubMed     Abstract available


  590. TERABE M, Gilbert MR
    Another layer of immune complication in glioblastoma: ICOS-ICOSL.
    Neuro Oncol. 2020 Jan 7. pii: 5697440. doi: 10.1093.
    PubMed    


  591. LAMBA N, Kearney RB, Mehanna E, Catalano PJ, et al
    Utility of claims data for identification of date of diagnosis of brain metastases.
    Neuro Oncol. 2020 Jan 6. pii: 5697047. doi: 10.1093.
    PubMed    


  592. PATEL RR, Verma V, Miller AB, Lin TA, et al
    Exclusion of Patients with Brain Metastases from Cancer Clinical Trials.
    Neuro Oncol. 2020 Jan 4. pii: 5695909. doi: 10.1093.
    PubMed    


    December 2019
  593. JARAIZ-RODRIGUEZ M, Talaveron R, Garcia-Vicente L, Pelaz SG, et al
    Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth and enhances survival in mouse models in vivo.
    Neuro Oncol. 2019 Dec 28. pii: 5688710. doi: 10.1093.
    PubMed     Abstract available


  594. NASSIRI F, Zadeh G
    How should we manage incidental meningiomas?
    Neuro Oncol. 2019 Dec 25. pii: 5686813. doi: 10.1093.
    PubMed    


  595. XUE J, Wang B, Ming Y, Liu X, et al
    Deep-learning-based Detection and Segmentation-assisted Management on Brain Metastases.
    Neuro Oncol. 2019 Dec 23. pii: 5684915. doi: 10.1093.
    PubMed     Abstract available


  596. LANGEN KJ, Galldiks N, Lohmann P
    Combined FET PET/ADC mapping: improved imaging of glioma infiltration?
    Neuro Oncol. 2019 Dec 20. pii: 5681898. doi: 10.1093.
    PubMed    


  597. HUANG RY, Guenette JP
    Non-invasive Diagnosis of H3 K27M Mutant Midline Glioma.
    Neuro Oncol. 2019 Dec 20. pii: 5681667. doi: 10.1093.
    PubMed    


  598. RUDA R, Soffietti R
    Does an Optimal Management of Brain Metastases from Oncogenic-Driver Non-Small Cell Lung Cancer Exist?
    Neuro Oncol. 2019 Dec 20. pii: 5681666. doi: 10.1093.
    PubMed    


  599. HAIDER AS, van den Bent M, Wen PY, Vogelbaum MA, et al
    Towards a standard pathological and molecular characterization of recurrent glioma in adults: a RANO effort.
    Neuro Oncol. 2019 Dec 17. pii: 5679607. doi: 10.1093.
    PubMed     Abstract available


  600. CLOUGHESY TF, Brenner A, de Groot JF, Butowski NA, et al
    A randomized controlled phase III study of VB-111 combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).
    Neuro Oncol. 2019 Dec 17. pii: 5679576. doi: 10.1093.
    PubMed     Abstract available


  601. BRENNER AJ, Peters KB, Vredenburgh J, Bokstein F, et al
    Safety and efficacy of VB-111, an anti-cancer gene-therapy, in patients with recurrent glioblastoma: results of a phase I/II study.
    Neuro Oncol. 2019 Dec 17. pii: 5679561. doi: 10.1093.
    PubMed     Abstract available


  602. ARNOLD A, Yuan M, Price A, Harris L, et al
    Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity.
    Neuro Oncol. 2019 Dec 16. pii: 5679447. doi: 10.1093.
    PubMed     Abstract available


  603. ENE CI, Kreuser SA, Jung M, Zhang H, et al
    Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma.
    Neuro Oncol. 2019 Dec 3. pii: 5650878. doi: 10.1093.
    PubMed     Abstract available


  604. RUSS JB, Weiss WA
    Conversations on mutism: risk-stratification for cerebellar mutism based on medulloblastoma subtype.
    Neuro Oncol. 2019 Dec 3. pii: 5650866. doi: 10.1093.
    PubMed    


    November 2019
  605. DAVIS FG, Smith TR, Gittleman HR, Ostrom QT, et al
    Glioblastoma incidence rate trends in Canada and the United States compared with England, 1995-2015.
    Neuro Oncol. 2019 Nov 30. pii: 5648949. doi: 10.1093.
    PubMed    


  606. CARROLL SL, Longo JF
    Salinomycin targets the genome of radioresistant cells in glioblastomas.
    Neuro Oncol. 2019 Nov 30. pii: 5648122. doi: 10.1093.
    PubMed    


  607. ANEJA S, Omuro A
    Imaging biomarkers for brain metastases: more than meets the eye.
    Neuro Oncol. 2019 Nov 28. pii: 5645031. doi: 10.1093.
    PubMed    


  608. CAM M, Charan M, Welker AM, Dravid P, et al
    DeltaNp73/ETS2 complex drives glioblastoma pathogenesis- targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma.
    Neuro Oncol. 2019 Nov 25. pii: 5640296. doi: 10.1093.
    PubMed     Abstract available


  609. DE GROOT J, Penas-Prado M, Alfaro-Munoz KD, Hunter K, et al
    Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.
    Neuro Oncol. 2019 Nov 22. pii: 5637917. doi: 10.1093.
    PubMed     Abstract available


  610. GEHRING K, Stuiver MM, Visser E, Kloek C, et al
    A pilot randomized controlled trial of exercise to improve cognitive performance in patients with stable glioma: a proof of concept.
    Neuro Oncol. 2019 Nov 21. pii: 5637916. doi: 10.1093.
    PubMed     Abstract available


  611. VAN DEN BENT M, Eoli M, Sepulveda JM, Smits M, et al
    INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFRamplified glioblastoma.
    Neuro Oncol. 2019 Nov 20. pii: 5634209. doi: 10.1093.
    PubMed     Abstract available


  612. LIU H, Sun Y, O'Brien JA, Franco-Barraza J, et al
    Necroptotic astrocytes contribute to maintaining stemness of disseminated medulloblastoma through CCL2 secretion.
    Neuro Oncol. 2019 Nov 15. pii: 5626144. doi: 10.1093.
    PubMed     Abstract available


  613. CAPDEVIELLE C, Desplat A, Charpentier J, Saggliocco F, et al
    HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53.
    Neuro Oncol. 2019 Nov 10. pii: 5618834. doi: 10.1093.
    PubMed     Abstract available


  614. DRUMM MR, Dixit KS, Grimm S, Kumthekar P, et al
    Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas.
    Neuro Oncol. 2019 Nov 10. pii: 5618827. doi: 10.1093.
    PubMed     Abstract available


  615. ARRILLAGA-ROMANY I, Odia Y, Prabhu VV, Tarapore RS, et al
    Biological activity of weekly ONC201 in adult recurrent glioblastoma patients.
    Neuro Oncol. 2019 Nov 8. pii: 5614983. doi: 10.1093.
    PubMed     Abstract available


  616. COOMANS MB, Dirven L, Aaronson NK, Baumert BG, et al
    Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?
    Neuro Oncol. 2019;21:1447-1457.
    PubMed     Abstract available


  617. WEI J, Chen P, Gupta P, Ott M, et al
    Immune biology of glioma associated macrophages and microglia: Functional and therapeutic implications.
    Neuro Oncol. 2019 Nov 3. pii: 5611251. doi: 10.1093.
    PubMed     Abstract available


  618. DAS A, Ramaswamy V
    Less treatment for Wingless Medulloblastoma: germline data re-emphasizes this.
    Neuro Oncol. 2019 Nov 3. pii: 5611252. doi: 10.1093.
    PubMed    


  619. FAN Q, An Z, Wong RA, Luo X, et al
    Betacellulin drives therapy-resistance in glioblastoma.
    Neuro Oncol. 2019 Nov 3. pii: 5611241. doi: 10.1093.
    PubMed     Abstract available


    October 2019
  620. VICTOR RR, Malta TM, Seki T, Lita A, et al
    Metabolic Reprogramming Associated with Aggressiveness Occurs in the G-CIMP-High Molecular Subtypes of IDH1mut Lower Grade Gliomas.
    Neuro Oncol. 2019 Oct 30. pii: 5609197. doi: 10.1093.
    PubMed     Abstract available


  621. SAUNDERS CN, Cornish AJ, Kinnersley B, Law PJ, et al
    Lack of association between modifiable exposures and glioma risk: A Mendelian randomisation analysis.
    Neuro Oncol. 2019 Oct 30. pii: 5609347. doi: 10.1093.
    PubMed     Abstract available


  622. BALASUBRAMANIAN SK, Sharma M, Venur VA, Schmitt P, et al
    Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis.
    Neuro Oncol. 2019 Oct 24. pii: 5606822. doi: 10.1093.
    PubMed     Abstract available


  623. PATEL SK, Hartley RM, Wei X, Furnish R, et al
    Generation of diffuse intrinsic pontine glioma mouse models by brainstem targeted in utero electroporation.
    Neuro Oncol. 2019 Oct 22. pii: 5602255. doi: 10.1093.
    PubMed     Abstract available


  624. YOGANANDA CGB, Shah BR, Vejdani-Jahromi M, Nalawade SS, et al
    A Novel Fully Automated Mri-Based Deep Learning Method for Classification of Idh Mutation Status in Brain Gliomas.
    Neuro Oncol. 2019 Oct 22. pii: 5602247. doi: 10.1093.
    PubMed     Abstract available


  625. SANTANA-CODINA N, Muixi L, Foj R, Sanz-Pamplona R, et al
    GRP94 promotes brain metastasis by engaging pro-survival autophagy.
    Neuro Oncol. 2019 Oct 22. pii: 5602253. doi: 10.1093.
    PubMed     Abstract available


  626. TESILEANU CMS, Dirven L, Wijnenga MMJ, Koekkoek JAF, et al
    Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
    Neuro Oncol. 2019 Oct 22. pii: 5602222. doi: 10.1093.
    PubMed     Abstract available


  627. IWATA R, Lee JH, Hayashi M, Dianzani U, et al
    ICOSLG-mediated regulatory T cell expansion and IL-10 production promote progression of glioblastoma.
    Neuro Oncol. 2019 Oct 22. pii: 5601905. doi: 10.1093.
    PubMed     Abstract available


  628. PLATTEN M
    Driving mesenchymal transition in glioblastoma.
    Neuro Oncol. 2019 Oct 19. pii: 5599736. doi: 10.1093.
    PubMed    


  629. JOHANNESSEN TA, Bjerkvig R
    A new chance for EGFR inhibition in glioblastoma?
    Neuro Oncol. 2019 Oct 19. pii: 5599734. doi: 10.1093.
    PubMed    


  630. GITTLEMAN H, Sloan AE, Barnholtz-Sloan JS
    An independently validated survival nomogram for lower grade glioma.
    Neuro Oncol. 2019 Oct 17. pii: 5588962. doi: 10.1093.
    PubMed     Abstract available


  631. BHATIA A, Birger M, Veeraraghavan H, Um H, et al
    MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors.
    Neuro Oncol. 2019 Oct 17. pii: 5588961. doi: 10.1093.
    PubMed     Abstract available


  632. IJAZ H, Koptyra M, Gaonkar KS, Rokita JL, et al
    Pediatric High Grade Glioma Resources from the Children's Brain Tumor Tissue Consortium (Cbttc).
    Neuro Oncol. 2019 Oct 15. pii: 5588066. doi: 10.1093.
    PubMed    


  633. ISLIM AI, Kolamunnage-Dona R, Mohan M, Moon RDC, et al
    A prognostic model to personalize monitoring regimes for patients with incidental asymptomatic meningiomas.
    Neuro Oncol. 2019 Oct 11. pii: 5585790. doi: 10.1093.
    PubMed     Abstract available


  634. RUBIN JB, Schlaggar BL
    To each, his/her own.
    Neuro Oncol. 2019;21:1217-1218.
    PubMed    


  635. WU CY, Chen CH, Lin CY, Feng LY, et al
    CCL5 of glioma-associated microglia/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase-2.
    Neuro Oncol. 2019 Oct 8. pii: 5583889. doi: 10.1093.
    PubMed     Abstract available


  636. KOMORI T
    The anticipated revision of the grading criteria for adult isocitrate dehydrogenase-mutant diffuse glioma within the neuro-oncology community.
    Neuro Oncol. 2019 Oct 5. pii: 5581618. doi: 10.1093.
    PubMed    


    September 2019
  637. SU X, Chen N, Sun H, Liu Y, et al
    Automated Machine Learning Based on Radiomics Features Predicts H3 K27M Mutation in Midline Gliomas of the Brain.
    Neuro Oncol. 2019 Sep 29. pii: 5575985. doi: 10.1093.
    PubMed     Abstract available


  638. FU Y, Wang D, Wang H, Cai M, et al
    TSPO deficiency induces mitochondrial dysfunction, leading to hypoxia, angiogenesis and a growth-promoting metabolic shift towards glycolysis in glioblastoma.
    Neuro Oncol. 2019 Sep 29. pii: 5575982. doi: 10.1093.
    PubMed     Abstract available


  639. RIVERO-HINOJOSA S, Kinney N, Garner HR, Rood BR, et al
    Germline Microsatellite Genotypes Differentiate Children with Medulloblastoma.
    Neuro Oncol. 2019 Sep 28. pii: 5575474. doi: 10.1093.
    PubMed     Abstract available


  640. VERBURG N, Koopman T, Yaqub MM, Hoekstra OS, et al
    Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study.
    Neuro Oncol. 2019 Sep 24. pii: 5573318. doi: 10.1093.
    PubMed     Abstract available


  641. TANNOUS BA, Badr CE
    An allosteric inhibitor of SHP2 effectively targets PDGFRalpha-driven glioblastoma.
    Neuro Oncol. 2019 Sep 17. pii: 5570971. doi: 10.1093.
    PubMed    


  642. BASHIR A, Mathilde Jacobsen S, Molby Henriksen O, Broholm H, et al
    Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).
    Neuro Oncol. 2019 Sep 6. pii: 5564094. doi: 10.1093.
    PubMed     Abstract available


    July 2019
  643. APPAY R, Dehais C, Maurage CA, Alentorn A, et al
    CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Neuro Oncol. 2019 Jul 12. pii: 5531923. doi: 10.1093.
    PubMed     Abstract available


    May 2019
  644. WESSELING P
    The ABCs of molecular diagnostic testing of CNS tumors: acceptance, benefits, costs.
    Neuro Oncol. 2019;21:559-561.
    PubMed    


    February 2019
  645. BARNHOLTZ-SLOAN JS
    Brain and central nervous system tumor statistics: access to accurate data for all countries is critical!
    Neuro Oncol. 2019;21:291-292.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: